

PUBLICATIONS

(Noted in Scientific Information's "Highly Cited Authors In Science" list, having been cited more than 36,000 times with an h-index score of 84)

Refereed Articles

1. Winchester RJ, Ebers GC, et al. B-cell Alloantigen 7a in multiple sclerosis. *Lancet* 1975;2:84.
2. Opelz G, Teresaki P, Myers L, Ellison G, Ebers GC, et al. The association of HLA antigens A3, B7, Dw2 with MS. *Tissue Antigens* 1977;9:54.
3. Espinoza LR, Ebers GC, Mountcastle W, Zabriskie JB. Cell-mediated immunity in multiplesclerosis. The International Symposium on the Histocompatibility Systems in Multiple Sclerosis. (ed. Torbin Fog). *Acta Neurol Scand* 1977;55(63):123.
4. Collins RC, Espinoza LR, Plank CR, Ebers GC, Rosenberg R, Zabriskie JB. A double blind trial of transfer factor vs. placebo in multiple sclerosis Patients. *Clin Exp Immunol* 1978;33:1-11.
5. Ebers GC, Zabriskie JB, Kunkel HG. Idiotypic determinants in SSPE and MS. *Clin Exp Immunol* 1979;35:67-75.
6. Ebers GC, Paty DW. HLA, The immune system and MS. *Clin Neurol Neurosurg* 1979 ;81:69-86.
7. Ebers GC. Anti-idiotypic sera in the study of MS CSF bands. *Trans Am Neurol Assoc* 1979;104:93-95.
8. Ebers GC, Paty DW. Alkaline isoelectric focusing in polyacrylamide gel of cerebrospinal fluid in multiple sclerosis. *Trans Am Neurol Assoc* 1979;104:230-233.
9. Tiwari J, Zander H, Teresaki P, et al. Multiple sclerosis in histocompatibility testing. *UCLA* 1980;687-692.
10. Ebers GC, Paty DW. CSF electrophoresis in one thousand patients. *Can J Neurol Sci* 1980;7(4):275-280.
11. Ebers GC, Paty DW. Studies in familial MS. *Trans Am Neurol Assoc* 1980;105:344-347.
12. Ebers GC, Paty DW. Optic neuritis in familial MS. *Neurology* 1981;31:1138-1142.
13. Feasby TE, Paty DW, Ebers GC, Fox A. Spinal cord swelling in multiple sclerosis. *Can J Neurol Sci* 1981;8(2):151-153.
14. Ebers GC, Paty DW, Stiller C, Nelson R, Seland T. HLA typing in MS sibling pairs. *Lancet* 1982;88-90.
15. Brett DD, Ferguson GC, Ebers GC. Percutaneous trigeminal rhizotomy in the treatment of trigeminal neuralgia secondary to multiple sclerosis. *Arch Neurol* 1982;39:219-221.
16. Ebers GC. A study of CSF idiotypes in MS. *Scand J Immunol* 1982; 16:151-161.
17. Vinuela FV, Fox AJ, Debrun GM, Feasby TE, Ebers GC. New perspectives in computed tomography of multiple sclerosis. *Am J Neuroradiology* 1982;3:277-281.
18. Dales S, Ebers G, Feasby T, Paty D. Conference Report: International Symposium on Multiple

- Sclerosis. *Can J Neurol Sci* 1982;8(4):333-338.
19. Ebers GC, Cripps J, Rudd A. Birth order and multiple sclerosis. *Acta Neurol Scand*;1982;66: 342-346.
 20. Ebers GC, Stewart J. In defence of Osler. *J Royal Soc Med* 1982;75:989.
 21. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. *Ann Neurol* 1983;13 3:227-231.
 22. Moulin D, Paty DW, Ebers GC. The predictive value of CSF electrophoresis in 'possible' MS. *Brain* 1983;106: 809-816.
 23. Noseworthy J, Wonnacott T, Paty DW, Feasby TE, Ebers GC. Multiple sclerosis after age 50. *Neurology* 1983;33:1537-1544.
 24. Ebers GC, Feasby TE. Optic neuritis and MS. *Can J Neurol Sci* 1983;9:79-80.
 25. Ebers GC. The genetics of MS. *Neurologic Clinics of North America*. 1983;1(3):645-654.
 26. Sullivan SN, Ebers GC. Gastrointestinal dysfunction in multiple sclerosis. *Gastroenterology* 1983;84(6).
 27. Weiner HL, Ebers GC. Development of simple trial protocols. *Arch Neurol* 1983;40(11):700.
 28. Ebers GC, Vinuela F, Feasby TE, Bass B. Multifocal CT enhancement in MS. *Neurology* 1984;34:341-346.
 29. Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and "optic neuritis" as paraneoplastic effects of bronchial carcinoma. *Neurology* 1984;4:788-791
 30. Bell DA, Rigby R, Stiller CR, Clark WF, Harth M, Ebers GC. HLA antigens in systemic lupus erythematosus: relationship to disease severity, age at onset, and sex. *J Rheumatology* 1984; 11(4):475-479.
 31. Ebers GC. Oligoclonal banding in MS. *Ann NY Acad Science* 1984; 436:206-212.
 32. Noseworthy J, Paty DW, Ebers GC. Neuroimaging in multiple sclerosis. *Neurologic Clinics*;1984;2(4) 759-777.
 33. Noseworthy J, Seland P, Ebers GC. Therapeutic trials in MS. *Can J Neurol Sci* 1984;11:355-362.
 34. Marshall WH, Barnard JM, Churchill D, Farid NR, Grandy R, Larsen B, Payne RH, Skanes VM, Ebers GC, Paty DW, Mervar H and Schroeder ML. Study of alleles of the second complement component (C2) on Canadian HLA haplotypes. *Tissue Antigens* 1984;23:229-239.
 35. Farrell MA, Kaufmann JCE, Gilbert JJ, Noseworthy JH, Armstrong HA, Ebers GC. Oligoclonal bands in multiple sclerosis: clinical-pathologic correlation. *Neurology* 1985;35(2):212-218.
 36. Ebers GC. Osler and neurology. *Can J Neurol Sci* 1985;12(3) 236-242.
 37. Ebers GC. Optic neuritis and multiple sclerosis. *Arch Neurol* 1985; 42(7):702-704.
 38. Christenson RH, Russell ME, Gubar KT, Silverman LM, Ebers GC. Oligoclonal banding in cerebrospinal fluid assessed by electrophoresis on agarose after centrifugal sample concentration through a microconcentrator membrane. *Clin Chem* 1985;31(4).

39. Harpur GD, Suke R, Bass BH, Bull SB, Noseworthy JH, Rice GPA, Ebers GC. A double-blind controlled study of hyperbaric oxygen in chronic stable multiple sclerosis. *Neurology* 1986;36(7):988-991.
40. Rice GPA, Armstrong H, Bulman DE, Paty DW, Ebers GC. Absence of antibody to HTLV I and HTLV III in sera of Canadian patients with multiple sclerosis and chronic myelopathy. *Ann Neurol* 1986;20(4):533-534.
41. Bogouslavsky J, Fox AJ, Carey LS, Vinitzki S, Bass B, Noseworthy JH, Ebers GC, Barnett HJM. Correlates of brain-stem oculomotor disorders in multiple sclerosis. *Magnetic resonance imaging. Arch Neurol* 1986;43:460-463.
42. Sorensen O, Collins A, Flintoff W, Ebers GC, Dales S. Probing for the human coronavirus OC43 in CNS tissue in multiple sclerosis. *Neurology* 1986;36:1604-1606.
43. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Grey T, Nelson R, Nicolle M, Brunet D. A population-based study of multiple sclerosis in twins. *New Engl J Med* 1986;315:1638-1642.
44. Weinshenker B, Ebers GC. The natural history of MS. *Can J Neurol Sci* 1987;14(3):255-261.
45. Ebers GC. Prognostic factors in multiple sclerosis. *Trans Assoc Life Insur Med Dir Am* 1987;70:171-176.
46. Duquette P, Murray TJ, Pleines J, Ebers GC, et al. Multiple sclerosis in childhood: Clinical profile in 125 patients. *J Pediatrics* 1987;111:359-363.
47. Bass B, Weinshenker B, Rice GPA, Noseworthy JH, Cameron MGP, Hader W, Bouchard S, Ebers GC. Tizanidine versus Baclofen in the treatment of spasticity in patients with multiple sclerosis: a double-blind study. *Can J Neurol Sci* 1988;15:15-19.
48. Bass BH, Armstrong H, Ebers GC, Noseworthy JH, Weinshenker B, Rice GPA. Interpretation of single band patterns in CSF protein electrophoresis. *Can J Neurol Sci* 1988;15:20-22.
49. Hader WJ, Elliott M, Ebers GC. Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada. *Neurology* 1988; 38(4):617-621.
50. Noseworthy JH, Bass BH, Vandervoort MK, Ebers GC, Rice GPA, Weinshenker BG, McLay CJL, Bell DA. The prevalence of primary Sjogren's syndrome in a multiple sclerosis population. *Ann Neurol* 1989;25(1):95-98.
51. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. *Brain* 1989;112:133-146.
52. Valberg LS, Flanagan PR, Kertesz A, Ebers GC. Abnormalities in iron metabolism in multiple sclerosis. *Can J Neurol Sci* 1989; 16:184-186.
53. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. *Neurology* 1988;38(12): 1830-1834.
54. Power C, Weinshenker BG, Dekaban GA, Ebers GC, Francis GS, Rice GPA. HTLV-1 associated myelopathy in Canada. *Can J Neurol Sci* 1989;16(3):330-335
55. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. *Brain* 1989;112:1419-1428.

56. Weinshenker BG, Hader W, Carriere W, Baskerville J, Ebers GC. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. *Neurology* 1989;39:1438-1440.
57. Noseworthy JH, Vandervoort MK, Ebers GC, et al. Acceptance of placebo-control trial design by progressive multiple sclerosis patients. *Neurology* 1989;39(4):606-607.
58. Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC. A referendum on clinical trial research in multiple sclerosis: The opinion of the participants at the Jekyll Island Conference. *Neurology* 1989;39(7):977-981.
59. Weinshenker B, Gilbert JG, Ebers GC. Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis. *J Neurol Neurosurg Psychiat* 1990;53:146-149.
60. Weinshenker B., Ebers GC. Familial and sporadic MS: a comparative study. *Neurology* 1990;40:1354-1358
61. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian cooperative multiple sclerosis study group. *The Lancet* 1991; 337(8739):441-446.
62. Sadovnick AD, Bulman D, Ebers GC. Parent-child concordance in multiple sclerosis. *Ann Neurol* 1991;29:252-255.
63. Bulman D, Sadovnick AD, Ebers GC. Age of onset in siblings concordant for MS. *Brain* 1991;114(II):937-950.
64. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of MS : a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. *Brain* 1991;114(II):1045-1056.
65. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of MS: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. *Brain* 1991; 114(II):1057-1067.
66. Weinshenker BG, Bass B, Karlik SJ, Ebers GC, Rice GPA. An open trial of OKT3 in patients with MS. *Neurology* 1991;41:1047-1052.
67. Bulman D, Armstrong H, Ebers GC. Allele frequencies of the third component of complement (C3) in MS patients. *J Neurol Neurosurg Psychiat* 1991;54(6): 554-555.
68. Walter M, Gibson W, Ebers GC, Cox DW. Susceptibility to multiple sclerosis associated with the proximal heavy chain variable region. *J Clin Invest* April 1991;87:1266-1273.
69. Sadovnick D, Bulman DE, Hashimoto L, D'Hooghe MB, Ebers GC. Influence of gender on susceptibility to MS in sibships. *Arch Neurol* 1991;48:586-588.
70. Ebers GC. Inheritance factors in multiple sclerosis. *Nova Scotia Medical Journal* 1992;71(2):54-58.
71. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. *Neurology* 1992; 42(5):991-994.
72. Bulman DE, Ebers GC. The geography of MS reflects genetic susceptibility. *J Tropical and Geographical Neurology* 1992;2:66-72.
73. Sadovnick AD, Ebers GC, Paty DW, Eisen K. Cause of death in patients attending multiple

- sclerosis clinics. *Neurology* 1991; 41(8):1193-1196.
74. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis - clinical features, neuropathology and diagnostic criteria. *Brain* 1992;115:495-520.
 75. Wiebe S, Lee DH, Karlik SJ, Hopkins M, Vandervoort MK, Wong C, Hewitt L, Rice GPA, Ebers GC, Noseworthy JH. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis: Clinical correlations and implications for classification of disease course. *Ann Neurol* 1992;32(5): 643-650.
 76. Weinshenker BG, Penman M, Ebers GC, Rice GPA. A double blind randomized crossover trial of Pemoline in fatigue associated with multiple sclerosis. *Neurology* 1992;42(1):1468-1471.
 77. Hashimoto L, Walter M, Cox D, Ebers GC. Immunoglobulin variable region polymorphisms and multiple sclerosis. *J Neuroimmunol* 1993;44(1):77-79.
 78. Sadovnick D, Ebers GC. Epidemiology of MS: A critical overview. *Can J Neurol Sci* 1993;20:17-29.
 79. Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: A review. *Neuroepidemiology* 1993;12:1-5.
 80. Sadovnick AD, Armstrong H, Rice GPA, Bulman D, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Metz L, Bell R, Duquette P, Gray T, Nelson R, Weinshenker B, Brunet D, Ebers GC. A population-based study of multiple sclerosis in twins: Update. *Ann Neurol* 1993; 33:281-285.
 81. INFB MS study group. Interferon beta-1b is effective in relapsing/remitting multiple sclerosis: I. Clinical results of a multicenter randomized trial. *Neurology* 1993;43:655-661.
 82. Paty DW, Li DKB, MS/MRI Study Group, INFB Multiple Sclerosis Study Group. Interferon-beta 1B is effective in relapsing/remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized double-blind, placebo-controlled trial. *Neurology* 1993;43:662-667.
 83. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman MF, Rice GPA, Grinwich KD, Cauvier H, Harris BJ, Ebers GC. An open trial evaluation of mitoxantrone Hc1 in the treatment of progressive multiple sclerosis. *Neurology* 1993;43:1401-1406.
 84. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. *Neurology* 1994; 44(1):16-20.
 85. Ebers GC. Cerebrospinal fluid in the diagnosis of multiple sclerosis. *Mult Scler: Clinical Issues* 1994; Vol.
 86. Ebers GC. Treatment of M.S. *The Lancet* 1994;343: 275-279.
 87. Ebers GC, Sadovnick AD. Association studies in multiple sclerosis. *J Neuroimmunol* 1994;53:117-122.
 88. Ebers GC, Sadovnick AD. The role of genetic factors in multiple sclerosis susceptibility. *J Neuroimmunol* 1994;54:1-17.
 89. Ebers GC. Genetics and multiple sclerosis - An overview. *Ann Neurol* 1994;36(Suppl):S12-14.
 90. Trejo V, Derom C, Vlietinck R, Ollier W, Silman A, Ebers GC, Derom R, Gregersen PK. X Chromosome inactivation patterns correlate with fetal-placental anatomy in monozygotic twin pairs: Implications for immune relatedness and concordance for autoimmunity. *Molecular Medicine* 1994;

- 1(1):62-70.
91. Lee DH, Vellet AD, Eliasziw M, Vidito L, Ebers GC, Rice GP, Hewett L, Dunlavy S. MR imaging field strength: Prospective evaluation of the diagnostic accuracy of MR for diagnosis of multiple sclerosis at 0.5 and 1.5 T1. *Radiology* 1995;194:257-262.
 92. Sadovnick AD, Ebers GC. Genetic factors in the pathogenesis of MS. *International MS Journal* 1995;1:17-24.
 93. Gaudet J, Hashimoto L, Sadovnick AD, Ebers GC. Is MS caused by an infection of adolescence and early adulthood: a case-control study of birth order position. *Acta Neurol Scand* 1995;91:19-21.
 94. Gaudet J, Hashimoto L, Sadovnick AD, Ebers GC. A study of birth order and multiple sclerosis in multiplex families. *Neuroepidemiology* 1995;14:188-192.
 95. Sibley WA, Ebers GC, Lublin FD, Paty DW, Reder At (manuscript and data analysis committee). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. *Neurology* 1995;45:1277-1285.
 96. Ebers GC, Sibley WA, Paty DW and the IFNB study group. Immunotherapy for multiple sclerosis: Clinical aspects and trials. *Acta Neurol Scand* 1995;91, Suppl. 161:54.
 97. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. *Nature* (1995) 377:150-151
 98. Rice GPA, Ebers GC. Treatment of multiple sclerosis. *The Female Patient* 20(9):31-45.
 99. Sadovnick AD, Ebers GC, Dymment D, Risch N and the Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. *The Lancet* 1996;347(9017):1728-1730.
 100. Ebers GC. Genetic Epidemiology of multiple sclerosis. *Curr Opin Neurol* 1996;9(3): 155-159.
 101. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, Armstrong H, Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O'Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Murray TJ, Pryse-Phillips W, Nelson R, Freedman M, Brunet D, Bouchard J-P, Hinds D, Risch N. A full genome search in multiple sclerosis. *Nature Genet* 1996;13:472-476.
 102. The IFNB MS Study Group & the UBC MS/MRI Analysis Group. Co-authors - Sibley WA, Ebers GC, Lublin FD, Paty DW, Reder AT. Neutralizing antibodies during treatment of multiple sclerosis with Interferon Beta-1b. *Neurology* 1996;47(4):889-894.
 103. Dymment DA, Sadovnick AD, Ebers GC. Genetics of multiple sclerosis (review). *Hum Mol Genet* 1997;6(10):1693-1698.
 104. Sadovnick AD, Dymment D, Ebers GC. Genetic epidemiology of multiple sclerosis. *Epidemiol Rev* 1997;19(1):99-106.
 105. Sadovnick AD, Ebers GC, Yee IML, Risch NJ. The effect of age of onset and parental disease status on sib risks for multiple sclerosis. *Neurol* 1998;50:719-723.
 106. Sadovnick AD, Ebers GC, Risch NJ & the Canadian Collaborative Study Group. Canadian Collaborative Project on Genetic Susceptibility of MS - Phase II: Rationale and method. *Can J Neurol Sci* 1998;25:216-221.
 107. PRISMS Study Group. Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. *Lancet* 1998;352:1498-1504.

141. Noseworthy JH, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Rice GPA, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Metz L, Shuster E & the Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic-Canadian Cooperative Trial of Sulfasalazine in active multiple sclerosis. *Neurology* 1998;51(5):1342-1352
108. Cottrell DA, Rice GPA, Hader W, Baskerville J, Koopman WJ, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis. *Brain* 1999a;122:625-639
109. Cottrell DA, Kremenchutzky M, Rice GPA, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. *Brain* 1999b;122:641-647.
110. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS. The relationship of MS to physical trauma and psychological stress. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1999;52:1737-1745.
111. Rice GPA, Ebers GC, Lublin FD, Knobler RL. Ibuprofen treatment versus gradual introduction of interferon β -1b in patients with MS. *Neurology* 1999;52:1893-1895.
112. Kremenchutzky M, Cottrell D, Rice GPA, Hader W, Koopman W, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. *Brain* 1999;122:1941-1949.
113. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. *Neurology* 1999;53:457-465.
114. Rice GPA, Lesaux J, Ebers GC, Oger J, Paszner B, Pary D. The evolution of neutralizing antibodies in patients taking beta interferon 1b. *Neurology* 1999;52:1277-1279.
115. Ebers GC. Modelling multiple sclerosis. *Nature Genet* 1999;23:258-259.
116. Sadovnick AD, Dircks A, Ebers GC. Genetic counselling in multiple sclerosis: risks to sibs and children of affected individuals. *Clinical Genetics* 1999;56:118-122.
117. Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C, Ebers GC and the Canadian Collaborative Study Group. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. *Neurology* 2000;54:729-732.
118. Hartung HP, Ebers GC, Soelberg-Sorensen P, Abramsky O, Kesselring J, Delwel GO. Management of relapsing-remitting multiple sclerosis: Diagnosis and treatment guidelines. *Eur J Neurol* 1999;6(suppl 1):S1-3 155.
119. Paty DW, Ebers GC, Lee D. et al. Magnetic resonance imaging results of the PRISM trial: A randomized, double-blind placebo-controlled study. *Ann Neurol* 1999;46:197-206.
120. Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P, Wingerchuk DM, Baskerville J, Rice GPA. The natural history of multiple sclerosis: a geographically based study: 8. Familial multiple sclerosis. *Brain* 2000;123:641-649.
121. Kremenchutzky M, Lee D, Rice GPA, Ebers GC. Diagnostic Brain MRI Findings in Primary Progressive Multiple Sclerosis. *Mult Scler* 2000;6:81-85.
122. Willer CJ, Ebers GC. Susceptibility to multiple sclerosis: interplay between genes and environment.

- Current Opinion in Neurology 2000; 3:241-247.
123. Racacho LJ, McLachlan RS, Ebers GC, Maher J, Bulman DE. Evidence favouring genetic heterogeneity for febrile convulsions. *Epilepsia* 2000;41 (2):132-139.
 124. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC and the North American Linomide Investigators. Linomide in relapsing and secondary progressive MS. Part I: Trial design and clinical results. *Neurology* 2000;9:1726-1733.
 125. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC; and the MRI Analysis Center of the University of Texas, and the North American Linomide Investigators. Linomide in relapsing and secondary progressive MS. Part II: MRI results. *Neurology* (2000) 9:1734-1741.
 126. Mandalfino P, Rice GPA, Smith A, Klein JL, Rystedt, Ebers GC. Bone Marrow Transplantation in MS. *J Neurol* (2000) 9: 691-695.
 127. European Group for Blood and Marrow Transplantation and the European Charcot Foundation. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis. *J Neurol* (2000) 247:376-382.
 128. Ebers GC, Yee IML, Sadovnick AD, Duquette P and the Canadian Collaborative Study Group.
 129. Conjugal multiple sclerosis: Population-based prevalence and recurrence risks in offspring. *Ann Neurol* (2000) 48:927-931.
 130. Sadovnick AD, Yee IML, Ebers GC and the Canadian Collaborative Study Group. Factors influencing sib risks for MS. *Clin Genet* (2000) 58:431-435.
 131. Ebers GC. The natural history of multiple sclerosis. *Neurol Sci* (2000) 21:S815-817.
 132. Ebers GC. Preventing Multiple Sclerosis? *The Lancet* 2001; 357: 1547.
 133. Dymant DA, Willer CJ, Scott B, Armstrong H, Cousin K, Ligers A, Hillert J, Rice G, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O'Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Pryse-Phillips W, Nelson R, Freedman M, Brunet D, Bouchard J-P, Sadovnick A.D, Risch N, Ebers GC. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. *Neurogenetics* 2001; 3: 145-151.
 134. Ligers A, Dymant DA, Willert CJ, Sadovnick AD, Ebers G, Risch N, Hillert J and the Canadian Collaborative Group. Evidence of Linkage with HLA-DR in DRB1*15-Negative Families with Multiple Sclerosis. *Am. J. Hum. Genet.* 2001 Oct; 69 (4):900-903.
 135. The Transatlantic Multiple Sclerosis Genetics Cooperative. A meta-analysis of genomic screens in Multiple Sclerosis. *Multiple Sclerosis* 2001; 7:3-11.
 136. Sadovnick AD, Yee IML, Ebers GC and the Canadian Collaborative Study Group. Recurrence risks to sibs of MS index cases: impact of consanguineous matings. *Neurology* 2001 Mar 27; 56(6):784-785.
 137. Rice G, Incurvaia B, Munari L, D'Amico R, Ebers G, Polman C, Filippini G. A Cochrane review of randomized, placebo-controlled trials of recombinant interferons in relapsing remitting multiple sclerosis: *Cochrane Library/Cochrane Database of Systematic Reviews*, 2001:4. CD002002.
 138. SPECTRIMS Study. Randomized trial of interferon beta-1a in secondary progressive multiple Sclerosis. 1. Clinical Results. *Neurology* June 2001; 56:1496-1504.

139. SPECTRIMS Study. Randomized trial of interferon beta-1a in secondary progressive multiple Sclerosis. 2. MRI results. *Neurology* 2 June 2001; 56:1506-1513.
140. Ebers GC. The Natural History of Multiple Sclerosis. *JNNP* 2001 Dec, 71 Suppl 2, ii16-ii19.
141. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 classical article] *Neurology* 2001 Dec; 57 (12 Suppl 5): S31-35.
142. Willer CJ, Sadovnick AD, Ebers GC. Microchimerism in autoimmunity in transplantation: potential relevance to multiple sclerosis. *Journal of Neuroimmunology* 2002; 126: 126-133.
143. Dyment DA, Steckley JL, Willer C, Sadovnick AD, Risch N, the Canadian Collaborative Study Project and Ebers GC. No evidence to support CTLA-4 as a susceptibility gene in Canadian MS families. *Journal of Neuroimmunology* 123 (2002) 193–198.
144. Dyment DA, Cader Z, Willer CW, Risch N, Sadovnick AD, Ebers GC. A multigenerational family with multiple sclerosis. *Brain* 2002 July; 125 (Pt 7):1474-1482.
145. Dyment DA, Ebers GC. An array of sunshine in multiple sclerosis. *The New England Journal of Medicine* 2002 Oct.; 347(18): 1445-1447.
146. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, Rice GP. Interferons in relapsing remitting multiple sclerosis: a systematic review. *Lancet* 2003 Feb; 361(9357): 545-552.
147. Herrera BM, Ebers GC. Progress in deciphering the genetics of multiple sclerosis. *Current Opinion in Neurology* 2003, 16:253-258.
148. Cader ZM, Noble-Topham S, Dyment DA, Cherny SS, Brown JD, Rice GPA, Ebers GC. Significant linkage to migraine with aura on chromosome 11q24. *Human Molecular Genetics* 2003; 12(19):2511-2517.
149. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC: Twin concordance and sibling recurrence rates in multiple sclerosis. *PNAS* 2003 October; 100(22):12877-12882.
150. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. *The Lancet Neurology* 2004; 3: 104-110.
151. Ebers GC. MS, stress and the rules of evidence. *Practical Neurology* 2004; 3(3): 66-69.
152. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW and the IFNB Multiple Sclerosis Study Group: Longitudinal analyses of the effects of neutralizing antibodies in relapsing-remitting multiple sclerosis patients on interferon beta –1b. *Multiple Sclerosis* 2004; 10: 126-138.
153. Dyment DA, Sadovnick AD, Willer CJ, Armstrong H, Cader ZM, Wiltshire S, Kalman B, Risch N, Ebers GC. An extended genome scan in 442 Canadian multiple sclerosis affected sibships: a report from the Canadian Collaborative Study Group. *Human Molecular Genetics* 2004; 13(10): 1005-1015.
154. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. *Brain* 2004; 127(Pt 5): 1009-1018.
155. Ebers GC, Sadovnick AD, Dyment DA, Yee IML, Willer CJ, Risch N. Parent-of origin effect in multiple sclerosis: observations in half-siblings. *Lancet* 2004; 363: 847-850.
156. Ebers GC. Natural history of primary progressive multiple sclerosis. *Multiple Sclerosis* 2004; 10:S8-S15.
157. Dyment DA, Steckley JL, Morrison K, Willer CJ, Cader MZ, DeLuca GC, Sadovnick AD, Risch N,

- Ebers GC. TCR beta polymorphisms and multiple sclerosis. *Genes and Immunity* 2004; 5: 337-342.
158. DeLuca GC, Ebers GC, Esiri MM. The extent of axonal loss in the long tracts in hereditary spastic paraplegia. *Neuropathology and Applied Neurobiology* 2004 Dec; 30(6): 576-584.
 159. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC, for the Canadian Collaborative Study Group. Timing of birth and risk of multiple sclerosis: population based study *BMJ*. 2005 Jan 15; 330(7483):120.
 160. Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln KR, Sadovnick AD, Risch N, Ebers GC. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance *Hum Mol Genet* 2005 Jul; 14(14):2019-2026.
 161. Francis GS, Rice, PA, Alsop JC and the PRISMS Study Group. Interferon β -1a in MS: results following development of neutralising antibodies in PRISMS. *Neurology* Jul 2005; 65:49-55.
 162. Cader MZ, Steckley JL, Dyment DA, McLachlan RS, Ebers GC. A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. *Neurology* 2005 Jul; 65(1):156-158.
 163. Willer CJ, Dyment DA, Sadovnick AD, Ebers GC. Maternal offspring HLA-DRB1 compatibility in multiple sclerosis. *Tissue Antigens* 2005 Jul; 66(1):44-47.
 164. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. *J Neurol* 2005; 252(Suppl 3):III/15-III/20. DOI 10.1007/s00415-005-2-12-4.
 165. Sadovnick AD, Yee IML, Ebers GC on behalf of the Canadian Collaborative Study Group. Multiple sclerosis and birth order: A longitudinal study. *Lancet Neurology* (online) 2005; doi:10.1016/S1474-4422(05)70170-8 (in press, October 2005).
 166. Wingerchuk DM, Lesaux J, Rice GPA, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting MS. *JNNP* 2005; 76:1294-1296.
 167. Lincoln MR, Montpetit A, Cader M Z, Saarela J, Dyment DA, Tiislar M, Ferretti V, Risch NJ, Peltonen L, Ebers GC, Hudson TJ. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. *Nat Genet* 2005; 37(10):1108-1112.
 168. Dyment DA, Yee IML, Ebers GC, Sadovnick AD for the Canadian Collaborative Study Group. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. *J Neurol Neurosurg Psychiatry* 2006; 77(2); 258-259.
 169. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study IX. Observations on the progressive phase of the disease. *Brain* 2006 Mar; 129(Pt 3): 584-594.
 170. Saarela J, Kallio S, Chen D, Montpetit A, Jokiaho A, Eva Choi, Asselta R, Bronnikov D, Lincoln M, Sadovnick, AD, Tienari P, Koivisto K, Palotie A, Ebers GC, Hudson TJ, Peltonen L. PRKCA shows association to multiple sclerosis in two populations. *PLoS-Genet*. 2006 Mar; 2(3).
 171. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. *Brain* 2006; 129: 1507-1516.
 172. Herrera BM, Cader MZ, Dyment DA, Tzenova-Bell J, Ramagopalan S, Lincoln MR, Orton S, Chao M, Sadovnick AD, Ebers GC. Follow-up investigation of twelve proposed linkage regions in multiple sclerosis. *Genes and Immunity* 2006; 7(5):366-371.
 173. Willer CJ, Herrera B, Morrison KM, Sadovnick AD, Ebers GC, for the Canadian Collaborative Study on Genetic Susceptibility to Multiple Sclerosis. Association between microchimerism and multiple

- sclerosis. *J Neuroimmun* 2006; 179(1-2):145-151.
174. Orton, SM, Herrera BM, Yee IM, Sadovnick AD, Ebers GC. Increasing sex ratio of multiple sclerosis in Canada. *Lancet Neurol* (2006) 5: 932-936.
 175. Ebers GC. Disease evolution in multiple sclerosis. *J Neurol* (2006) 253 Suppl 6:vi3-vi8.
 176. Ramagopalan SV, Dyment DA, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC. Clustering of autoimmunity in multiple sclerosis? *Lancet Neurology* 2007;Mar;6(3):206-7.
 177. Ramagopalan SV, DeLuca GC, Morrison KM, Herrera BM, Dyment DA, Orton SM, Bihoreau MT, Degenhardt A, Pugliatti M, Sadovnick AD, Sotgiu A, Ebers GC. No Effect of APOE and PVRL2 on Multiple Sclerosis Clinical Outcome. *Journal of Neuroimmunology* 2007; 86(102):156-160.
 178. DeLuca GC, Ramagopalan SV, Cader MZ, Dyment DA, Herrera BM, Orton S, Degenhardt A, Pugliatti M, Sadovnick AD, Sotgiu S, GC Ebers GC. The Role of Hereditary Spastic Paraplegia Related Genes in Multiple Sclerosis: A Study of Disease Susceptibility and Clinical Outcome. *Journal of Neurology* 2007;254 (9):1221-1226.
 179. Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC for the Canadian Collaborative Study Group. Autoimmune disease in families with multiple sclerosis: a population-based study. *Lancet Neurology* 2007;July 6 (7):604-610
 180. Herrera BM, Ramagopalan SV, Orton S, Chao MJ, Yee I, Sadovnick AD, Ebers GC. Parental transmission of MS in a population-based Canadian cohort. *Neurology* 2007; 69:1208-1212
 181. Sadovnick, AD, Duquette P, Herrera B, Yee IML, Ebers GC. A timing-of-birth effect on multiple sclerosis clinical phenotype. *Neurology* (2007) 69:60-62
 182. Daumer M, Held U, Ickstadt K, Heinz M, Schach S, Ebers G. Reducing the probability of false positive research findings by pre-publication validation - experience with a large multiple sclerosis database. *BMC Medical Research Methodology* 2008, 8:18 (10 Apr 2008)
 183. Giovannoni G, Ebers G. Multiple sclerosis: the environment and causation. *Curr Opin Neurol* (2007) 20:261-268
 184. Chao MJ, Barnardo MCNM, Lui GZ, Lincoln MR, Ramagopalan SV, Herrera BM, Dymment DA, Sadovnick AD, and Ebers GC. Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. *Hum Mol Genet* (2007) 16 (16): 1951-1958.
 185. Dymment DA, Cader MZ, Herrera BM, Ramagopalan SV, Orton SM, Chao M, Willer CJ, Sadovnick AD, Risch N, and Ebers GC. A genome-scan in a single pedigree with a high prevalence of multiple sclerosis. *JNNP* 2008; 79 (12): 158-162.
 186. Dymment DA and Ebers GC. Microsatellites and genome scans – a GAMES postscript. *Journal of Neuroimmunology* Vol 190, issue 1-2, pages 5
 187. Ramagopalan SV, Dymment DA, Morris AP, Herrera BM, DeLuca GC, Lincoln MR, Orton SM, Chao MJ, Sadovnick AD, Ebers GC, "The Inheritance of Resistance Alleles in Multiple Sclerosis", *PLOS Genetics* 2007 September; 3(9): 1607-1613.
 188. Herrera BM, Cader MZ, Dymment DA, Bell, JT, DeLuca GC, Willer CJ, Lincoln MR, Ramagopalan SV, Chao MJ, Orton S, Sadovnick AD and Ebers GC. Multiple sclerosis susceptibility and the X chromosome. *Multiple Sclerosis* 2007;13; 7: 856-864.
 189. Willer CJ, Dymment DA, Cherny S, Ramagopalan SV, Herrera BM, Morrison KME, Sadovnick AD,

- Risch NJ, Ebers GC. A genome-wide scan in forty large pedigrees with multiple sclerosis. *J Hum Genet*, 2007;52(12):955-962.
190. Ramagopalan S, Herrera B, Bell J, Dymment D, DeLuca G, Lincoln M, Orton S, Chao M, Sadovnick A, Ebers G. Parental transmission of HLA-DRB*15 in multiple sclerosis. *Human Genetics* 2008; 122(6): 661-663.
 191. DeLuca GC, Ramagopalan SV, Herrera BM, Dymment DA, Lincoln MR, Montpetit A, Pugliatti M, Barnardo MC, Risch NJ, Sadovnick AD, Chao M, Sotgiu S, Hudson TJ, Ebers GC. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. *PNAS* 2007 Dec 26;104(52):20896-901.
 192. Dymment DA, Cader MZ, Datta A, Broxholme SJ, Cherny SS, Willer CJ, Ramagopalan S, Herrera BM, Orton S, Chao M, Sadovnick AD, Hader M, Hader W, Ebers GC. A first stage genome-wide screen for regions shared identical-by-descent in hutterite families with multiple sclerosis. *Am J Med Genet B Neuropsychiatr Genet*. 2008 Jun 5;147B(4):467-72.
 193. Ebers GC. Environmental factors and multiple sclerosis. *Lancet Neurology* 2008;7(3):268-277.
 194. Ramagopalan SV, Ebers GC .Genes for Multiple Sclerosis. (Commentary) *The Lancet* 2008;371(9609).
 195. Hoppenbrouwers IA, Liu F, Aulchenko YA, Ebers GC, Oostra BA, van Duijn C, Hintzen RQ. Maternal Transmission of Multiple Sclerosis in a Dutch Population. 2008.*Arch Neurol*;65(3): 345-348.
 196. Hoppenbrouwers IA, Aulchenko YS, Ebers GC, Ramagopalan SV, Oostra BA, van Duijn CM, Hintzen RQ. . EVI5 is a risk gene for multiple sclerosis. *Genes and Immunity* 2008;9(4):334-337.
 197. Ramagopalan SV, Dymment DA, Herrera BM, Deluca GC, Lincoln MR, Orton SM, Handunnetthi L, Chao MJ, Sadovnick DA, Ebers GC. Parental non-inherited HLA resistance alleles do not confer protection against multiple sclerosis. *Journal of Neuroimmunology* 2008;196(1-2):170-172.
 198. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. *Neurology* 2008;71:624-631.
 199. Herrera BM, Ramagopalan SV, Lincoln MR, Orton SM, Chao MJ, Sadovnick AD, Ebers GC. Parent- of-origin effects in MS. Observations from avuncular pairs. *Neurology* 2008;71(11):799-803.
 200. Chao MJ, Barnardo CNM, Lincoln MR, Ramagopalan SV, Herrera BM, Dymment DA, Montpetit A, Sadovick AD, Knight JC, Ebers GC. HLA class 1 alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. *PNAS* 2008; 105 (35):13069-13074.
 201. Ebers GC, Daumer M. Natural History of Multiple Sclerosis. *EjoN* 2008; 15:881-882.
 202. Ramagopalan SV, Valdar W, Dymment DA, DeLuca GC, Orton S-M et al. No effect of preterm birth on the risk of multiple sclerosis: A population based study. *BMC Neurology* 2008; 8, 1 August 2008, Article number 30.
 203. Orton S, Morris AP, Herrera BM, Ramagopalan SV, Yun F, Lincoln MR, Chao MJ, Vieth R, Sadovnick AD, Ebers GC, for the Canadian Collaborative Study Group, Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. *American Journal of Clinical Nutrition* 2008;88 (2); 441-447.
 204. Ramagopalan SV, Dymment DA, Herrera BM, DeLuca GC, Lincoln MR, Orton SM, Handunnetthi L, Chao MJ, Sadovnick AD and Ebers. GC. Methylation of class II transactivator gene promoter IV is

- not associated with susceptibility to Multiple Sclerosis. *BMC Medical Genetics* 2008; 9, article number 63. doi:10.1186/1471-2350-9-63.
205. Ramagopalan SV, DeLuca GC, Morrison KM, Herrera BM, Dymont DA, Lincoln MR, Orton S-M, Chao MJ, Degenhardt A, Pugliatti M, Sadovnick AD, Sotgiu S, Ebers GC. An Analysis of 45 Candidate Genes for Disease Modifying Activity in Multiple Sclerosis. *Journal of Neurology* 2008 June 20, epub ahead of print. DOI 10.1007/s00415-008-0878-7.
 206. Ramagopalan SV, DeLuca GC, Degenhardt A, Ebers GC. The Genetics of Clinical Outcome in Multiple Sclerosis. *Journal of Neuroimmunology*. 2008;201-202: 183-199.
 207. Ramagopalan SV, Cukjati M, Černilec M, DeLuca GC, Dymont DA, Degenhardt A, Sadovnick AD, Čurin Šerbec V, Ebers GC and Duquette P. Mutations in the Hemochromatosis Gene and the Clinical Outcome of Multiple Sclerosis. *Journal of Neuroimmunology* 2008;203(1):104-107.
 208. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, Lundström W, Greiner E, Sadovnick AD, Goossens D, Van Broeckhoven C, Del-Favero J, Ebers GC, Oostra BA, van Duijn CM & Hintzen RQ. Genetic variation in the KIF1B locus determines susceptibility to multiple sclerosis. *Nature Genetics* 2008;40:1402 – 1403.
 209. Ramagopalan SV, Dymont DA, Ebers GC. Genetic Epidemiology: the use of old and new tools for multiple sclerosis. *Trends in Neuroscience* 2008;31(12):645-652.
 210. Ebers. MS and Autoimmune disorders. *Neurogenetics* 2009;10(1):1.
 211. Ramagopalan SV, Herrera BM, Valdar W, Dymont DA, Orton S-M, Yee I, Criscuoli M, Atkins K, Ebers GC, Sadovnick AD. No effect of Birth Weight on the Risk of Multiple Sclerosis: A Population Based Study. *Neuroepidemiology* 2008;31:181-184.
 212. Chao MJ, Ramagopalan SV, Herrera BM, Lincoln MR, Dymont DA, Sadovnick A, D'Esposito F, Ebers GC. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. *Human Molecular Genetics* 2009;18(2):261-266.
 213. Daumer M, Neuhaus A, Morrissey S, Hintzen F, Ebers GC. Magnetic resonance imaging as an outcome in MS clinical trials. *Neurology* 2009; 72(8):705-711.
 214. Ramagopalan SV, Maugeri N, Dymont DA, Lincoln MR, Orton SM, DeLuca GC, Herrera BM, Handunnetthi L, Chao M, Wicks K, Sadovnick AD, Ebers GC, Knight JC. Expression of the multiplesclerosis associated allele HLA-DRB1*1501 is influenced by vitamin D. *PLoS Genet*. 2009 February; 5(2): e1000369. Published online 2009 February 6. doi: 10.1371/journal.pgen.1000369.
 215. Ramagopalan et al. An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene. *BMC Medical Genetics* 2009;10:10.
 216. Ramagopalan SV, Valdar W, Dymont DA, DeLuca GC, Yee IM, Giovannoni G, Ebers GC, Sadovnick AD. Association of Infectious Mononucleosis with multiple sclerosis: a population based study. *Neuroepidemiology*. 2009;32:257-262 .
 217. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dymont DA, Orton SM, Yee IM, Ebers GC, Sadovnick AD. Age of puberty and the risk of multiple sclerosis: a population based study. *European Journal of Neurology* 2009;16:342-347.
 218. Ramagopalan SV and Ebers GC. Epistasis: Multiple Sclerosis and the major histocompatibility complex. *Neurology* 2009;72:566-567.
 219. Pickin M, Cooper CL, Chater T, O'Hagan A, Abrams KR, Cooper NJ, Boggild M, Palace J, Ebers G,

- Chilcott J, Tappenden P, Nicholl J. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future. *BMC Neurology* 2009;9:1.
220. Lincoln MR, Ramagopalan SV, Chao MJ, Herrera BM, DeLuca GC, Orton S-M, Dymment DA, Sadovnick DA, Ebers GC. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. *PNAS* 2009.
221. D'Netto MJ, Ward H, Morrison KM, Ramagopalan SV, Dymment DA. Risk alleles for multiple sclerosis in multiplex families. *Neurology* 2009;72:1984-1988.
222. Ramagopalan SV, Yee IM, Dymment DA, Orton S-M, Marrie RA, Sadovnick AD, Ebers GC for the Canadian Collaborative Study Group. Parent-of-origin effect in multiple sclerosis: observations from interracial matings. *Neurology* 2009;73(8):602-605.
223. Ebers GC. The Emperor's New Clothiers. *Multiple Sclerosis International Journal* 2009;16 (1), pp. 3-4.
224. Sadovnick A, D'Netto MJ, Yee Irene M, Guimond C, Reis J, Dymment DA, Ebers GC. Age of Onset in Concordant Twins and Other Relative Pairs With Multiple Sclerosis. *American Journal of Epidemiology* 2009; 170(3):289-296.
225. Ramagopalan SV, Knight JC, Ebers GC. Epistasis: multiple sclerosis and the major histocompatibility complex. *Current Opinion in Neurology* 2009; 22:219-225.
226. Ramagopalan SV, Morrison KM, Para A, Handel A, Disanto G, Handunnetthi L, Orton SM, Sadovnick AD, Ebers GC. Variants in ST8SIA1 do not play a major role in susceptibility to multiple sclerosis in Canadian families. *Journal of Neuroimmunology* 2009;212:142-144.
227. Ramagopalan SV, Byrnes JK, Dymment DA, Guimond C, Handunnetthi L, DiSanto G, Yee IM, Ebers GC, Sadovnick AD. Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. *Journal of Human Genetics* 2009;54(9):547-549.
228. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K and Konieczny A and the Investigators of the 16-Year Long-Term Follow-Up Study. Long-term follow up of the original Interferon- β 1b Trial in Multiple Sclerosis: Design and lessons from a 16-Year Observational Study. *Clinical Therapeutics* 2009;31(8):1724-1736.
229. Ramagopalan SV and Ebers GC Multiple sclerosis: major histocompatibility complexity and antigen presentation. *Genome Med.* 2009;1(11):105.
230. Clanet M, Ebers GC. MS Forum Workshop: looking ahead: advances in multiple sclerosis in the next decade. *Int MS J.* 2009 Jun;16(2):67-70.
231. Rice GPA, Ebers G, Fredrikson S, Tesser F, Filippini G. Interferon beta for secondary progressive Multiple Sclerosis. *Cochrane Review of Systematic Reviews* (1) art number CD005181
232. Isobe N, Matsushita T, Yamasaki R, Ramagopalan SV, Kawano Y, Nishimura Y, Ebers GC, Kira J. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. *Mult Scler* 2010;16(2):147-155.
233. Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC. Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. *Genes and Immunity* 2010;11(2):99-112.
234. Hoppenbrouwers IA, Aulchenko YS, Ebers GC, Ramagopalan SV, Oostra BA, van Duijn CM, Hintzen RQ. Replication of CD58 and CLEC16A as genome-wide significant risk genes for multiple sclerosis. *J Hum Genet* 2009;54:676-680.

235. Alcina A, Ramagopalan SV, Catalá-Rabasa A, Fedetz M, Ndagire D, Fernández O, Leyva L, Arnal C, Delgado C, Lucas M, Izquierdo G, Ebers GC, Matesanz F. Hexose-6-phosphate dehydrogenase (H6PD) a new risk gene for multiple sclerosis. *Eur J Hum Genet* 2010;18(5):618-620.
236. Degenhardt A, Ramagopalan SV, Scafari A, Ebers G. Clinical Prognostic Factors in Multiple Sclerosis: A Natural History Review. *Nature Reviews Neurology* 2009;5:672-682.
237. Handel AE, Handunnetthi L, Ebers GC, Ramagopalan SV. Type 1 diabetes mellitus and multiple sclerosis: common etiological features. *Nat Rev Endocrinol* 2009;5:655-664.
238. Ramagopalan SV, Link J, Byrnes JK, Dyment DA, Giovannoni G, Hintzen RQ, Sundqvist E, Kockum I, Smestad C, Lie BA, Harbo HF, Padyukov L, Alfredsson L, Olsson T, Sadovnick AD, Hillert J, Ebers GC. HLA-DRB1 and Month of Birth in Multiple Sclerosis. *Neurology* 2009;73(24):2107-2111.
239. Orton SM, Ramagopalan SV, Brocklebank D, Herrera BM, Dyment DA, Yee IM, Sadovnick AD, Ebers GC. Effect of immigration on multiple sclerosis sex ratio in Canada: the Canadian Collaborative Study. *J Neurol Neurosurg Psychiatry* 2010; 81:31-36.
240. Ramagopalan SV, Byrnes J, Orton S, Dyment DA, Guimond C, Yee I, Ebers G, Sadovnick D. Sex-Ratio of Multiple Sclerosis and Clinical Phenotype: *EJON* 2010;17(4):634-637.
241. Jadagic M, Colacios C, Nohra R, Dejean AS, Beyeen AD, Khademi M, Casemayou A, Lamouroux L, Duthoit C, Papapietro O, Sjöholm L, Bernard I, Lagrange D, Dahlman I, Lundmark F, Oturai AB, Soendergaard HB, Kempainen A, Saarela J, Tienari PJ, Harbo HF, Spurkland A, Ramagopalan SV, Sadovnick DA, Ebers GC, Seddighzadeh M, Klareskog L, Alfredsson L, Padyukov L, Hillert J, Clanet M, Edan G, Fontaine B, Fournié GJ, Kockum I, Saoudi A, and Olsson T. A role for VAV1 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. *Sci Transl Med* 2009;1(10):10ra21.
242. Ebers GC. Month of birth and Multiple Sclerosis Risk in Scotland. *Eur Neurol* 2010;63:41-42.
243. Handel AE, Ebers GC, Ramagopalan SV. Epigenetics: molecular mechanisms and implications for disease. *Trends in Molecular Medicine* 2010;16:7-16.
244. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. *Nature Reviews Neurology* 2010;6:156-166.
245. Handel AE, DeLuca GC, Morahan J, Handunnetthi L, Sadovnick AC, Ebers GC, Ramagopalan SV. No evidence for an effect of DNA Methylation on multiple sclerosis severity at HLA-DRB1*15 or HLA-DRB5. *Journal of Neuroimmunology* 2010; 223(102):120-123. Ramagopalan SV, Dyment DA, Guimond C, Yee I, Ebers G, Sadovnick D. No Effect of Parental Age on Risk of Multiple Sclerosis: A Population Based Study. *Neuroepidemiology* 2010;34:106–109.
246. Handel AE, Handunnetthi L, Giovannoni G, Ebers GC, Ramagopalan SV. Genetic and Environmental Factors and the Distribution of Multiple Sclerosis. *European Journal of Neurology* 2010;17(9):1210-1214.
247. Ramagopalan SV, Dyment DA, Guimond C, Orton S-M, Yee IM, Ebers GC, Sadovnick AD. Childhood Cow's Milk Allergy and the Risk of Multiple Sclerosis: a population-based study. *J Neurol Sci* 2010;291(1-2):86-88.
248. Scafari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M and Ebers GC. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. *Brain* 2010 *Brain* 2010 133(7):1914-1929.

249. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann, Konieczny A. Cross-sectional study assessing long-term safety of interferon- β -1b for relapsing-remitting MS. *Neurology* 2010;74(23):1877-1885.
250. Handunnetthi L, Ramagopalan SV, and Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. *Neurology* 2010;74:1905-1910.
251. Ebers GC. Outcome measures were flawed. *BMJ* 2010;340:c2707.
252. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A for the investigators of the 16-year Long Term Follow-Up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. *JNNP* 2010;81:907-912. doi:10.1136/jnnp.2009.204123
253. Armstrong R, Elston J, Hatton C, Ebers G. De novo relapsing-remitting multiple sclerosis following autologous stem cell transplantation. *Neurology* 2010;75(1):89-91.
254. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton S-M, Watson CT, Morahan JM, Giovannoni G, Ponting CP, Ebers GC and Knight JC. A ChIP-seq defined genome-wide map of vitamin D receptor binding: implications for disease and evolution. *Genome Research* 2010;20(10):1352-1360.
255. Ramagopalan SV, Ebers GC. Sequencing the multiple sclerosis genome: more questions than answers. *Lancet Neurology* 2010;9(8):757-759.
256. Chao MJ, Herrera BM, Ramagopalan SV, DeLuca G, Handunnetthi L, Orton SM, Lincoln MR, Sadovnick AD, Ebers GC. Parent-of-origin effects at the major histocompatibility complex in multiple sclerosis. *Human Molecular Genetics* 2010;19(18): 3679–3689.
257. Watson CT, Ramagopalan SV, Morrison KM, Ebers GC, Breden F. IGHV4-39 deletion polymorphism does not association with risk or outcome of multiple sclerosis. *Journal of Neuroimmunology* 2010;225(1-2):164-166.
258. Chao MJ, Ramagopalan SV, Herrera BM, Orton SM, Handunnetthi L, Lincoln MR, Dymont DA, Sadovnick AD, Ebers GC. MHC Transmission: Insights into Gender Bias in MS susceptibility. *Neurology* 2011;76(3):242-246.
259. Watson CT, Para AE, Lincoln MR, Ramagopalan SV, Orton SM, Morrison KM, Handunnetthi L, Handel AE, Chao MJ, Morahan J, Sadovnick AD, Breden F and Ebers GC. Revisiting the T-cell receptor alpha/delta locus and possible associations with multiple sclerosis. *Genes and Immunity* 2011;1-8
260. DiSanto G, Magalhaes S, Handel A, Morrison KM, Sadovnick AD, Ebers GC, Banwell B, Bar-Or A on behalf of the Canadian Pediatric Demyelinating Disease Network. HLA-DRB1 Confers Increased Risk of Pediatric-Onset MS in Children with Acquired Demyelination. *Neurology* 2011
261. Orton SM, Wald L, Confavreux C, Vukusic S, Krohn JP, Ramagopalan SV, Herrera BM, Sadovnick AD, Ebers GC. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. *Neurology* 2011; 76: 425-431.
262. Ramagopalan, S.V., Hoang, U., Seagroatt, V., Handel, A., Ebers, G.C., Giovannoni, G., Goldacre, M.J. Geography of hospital admissions for multiple sclerosis in England and comparison with the geography of hospital admissions for infectious mononucleosis: A descriptive study. *JNNP* 2011; 82 (6): 682-687.
263. Handel AE, Jarvis L, McLaughlin R, Fries A, Ebers GC and Ramagopalan SV. The epidemiology of multiple sclerosis in Scotland: inferences from hospital admissions. *PLoS One* 2011;6(1):e14606

264. Orton SM, Ramagopalan SV, Para, AW, Lincoln, MR, Handunnetthi, LH, Chao MC, Morahan J, Morrison KM, Sadovnick AD, and Ebers GE. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians: The Canadian Collaborative Study Group. *J Neurol Sci* 2011; 305:116-120.
265. Ramagopalan S, Handel AE, Giovannoni G, Rutherford Siegel S, Ebers GC, Chaplin G. Relationship of UV exposure to prevalence of multiple sclerosis in England. *Neurology* 2011; 76(16):1410-1414.
266. Banwell B et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. *The Lancet Neurology* 2011; 10(5):436-445.
267. Ramagopalan SV et al. Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis. *Archives of Neurology* 2011;68(4):469-472.
268. Ebers GC, Rudick R, Sormani MP et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS. *Neurology* 2011;76:1025
269. Ramagopalan SV, Guimond C, Criscuoli M, Dymont DA, Orton S-M, Yee IM, Ebers GC, Sadovnick D. Congenital Abnormalities and Multiple Sclerosis. *BMC Neurology* 2010; 10:115doi:10.1186/1471-2377-10-115.
270. Burrell AM, Handel AE, Ramagopalan SV, Ebers GC, Morahan JM. Epigenetic mechanisms in multiple sclerosis and the MHC. *Discov Med* 2011;11(58):187-196.
271. Ramagopalan SV, Guimond C, Dymont DA, Yee IM, Ebers GC, Sadovnick AD. Early life child exposure and the risk of multiple sclerosis: A population based study, *Journal of the Neurological Sciences* 2011;307:162-163.
272. Handel AE, DiSanto G, Jarvis L, McLaughlin R, Fries A, Ebers GC, Ramagopalan SV. Seasonality of admissions with multiple sclerosis in Scotland. *Eur J Neurol.* 2011;18(8):1109-11.
273. Berlanga-Taylor A, DiSanto G, Ebers GC, Ramagopalan SV. Vitamin D-gene interactions in multiple sclerosis. *Journal of the Neurological Science* 2011;311:32-36.
274. Babron MC, Perdry H, Handel AE, Ramagopalan SV, Damotte V, Fontaine B, Müller-Myhsok B, Ebers GC and Clerget-Darpoux F..Determination of the real effect of genes identified in GWAS: the example of IL2RA in multiple sclerosis. *European Journal of Human Genetics* 2012;20(3):321-325.
275. Thompson MD et al. Chromosome 1p36 in migraine with aura: association study of the 5HT1D locus. *NeuroReport* 2012;23:45-48.
276. DiSanto G et al. Vitamin D and multiple sclerosis hospital admissions in Scotland. *QJM* 2011(104):1001-1003.
277. Ramagopalan SV et al. Rare variants in the CYP27B1 gene associated with multiple sclerosis. *Annals of Neurology* 2011;70(6):881-886.
278. Casserly C, Ebers GC. Relapses do not matter in relation to long-term disability: Yes. *MSJ* 2011;17(12): 1412-1414.
279. Scalfari A et al. Age and Disability Accumulation in multiple sclerosis. *Neurology* 2011;77(13):1246-1252.

280. Goodin DS et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β -1b trial in multiple sclerosis. *JNNP* 2012;83(3):282-287.
281. Disanto et al. Seasonal Distribution of Psychiatric Births in England. *PLoS ONE* 2012; 7(4):pg:e34866
282. Goodin D, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone T, and Knappertz V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN β -1b trial. *Neurology* 2012; 78(17): 1315-1322.
283. Disanto G et al. Vitamin D receptor binding, chromatin states and association with MS. *Human Molecular Genetics* 2012. Available online May 16 2012.
284. Dymment DA, Cader M Zameel, Chao M, Dymment DA, Cader M Zameel, Chao M, Lincoln MR, Morrison KM, Disanto G, Morahan JM, DeLuca GC, Sadovnick AD, Lepage P, Monpetit A, Ebers GC, and Ramagopalan SV. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. *Neurology* 2012 ;79 (5):406-411.
285. Ramagopalan S, Yee I, Byrnes J, Guimond C, Ebers G, Sadovnick D. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. *JNNP* 2012;83(8):793-795.
286. Lincoln M, Ebers G. Robert Whytt, Benjamin Franklin and the First Probable Case of Multiple Sclerosis. *Annals of Neurology* 2012; 72 (3): 307-311.
287. Disanto, G., Chaplin, G., Morahan, J.M., Giovannoni, G., Hypponen, E., Ebers, G.C., Ramagopalan, S.V. Month of birth, vitamin D and risk of immune mediated disease: A case control study. *BMC Medicine* 2012;10:69.
288. La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S, Filippini G. Interferon β for secondary progressive multiple sclerosis: a systematic review. *JNNP* 2013; 84 (4):pp. 420-426.
289. Beyan Huriya et al. Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. *Genome Res.* 2012. Published in Advance August 23, 2012, doi:10.1101/gr.134304.
344. Scalfari A, Neuhaus A, Daumer M, DeLuca GC, Muraro PA, Ebers GC. Early relapses, onset of progression and late outcome in multiple sclerosis. (*Archives of Neurology*) *JAMA Neurol.* 2013;70(2):214-222.
345. Ragnedda G et al. Protein-Protein Interaction Analysis Highlights Additional Loci of Interest for Multiple Sclerosis. *PLOS ONE* October 2012;7(10):e46730
347. Goodin DS et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFN β -1b study. *BMJ Open* 2012;2:e001972.
292. Czyz, W., Morahan, J.M., Ebers, G.C., Ramagopalan, S.V. Genetic, environmental and stochastic factors in monozygotic twin discordance with a focus on epigenetic differences. *BMC Medicine* 2012, pp93 *BMC Medicine* 2012, 10:93 doi:10.1186/1741-7015-10-93
293. Galea I et al. A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis. *European Journal of Neurology* 2013; 20(7):1107–1109. DOI: 10.1111/ene.12016
294. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry* 2013. Online first 13 March 2013

295. Ramagopalan SV, Lee JD, Yee IM, Guimond C, Traboulsee AL, Ebers GC, Sadovnick AD, Association of smoking with risk of multiple sclerosis: a population-based study. *Journal of Neurology* 2013; **260** (7):1778-1781. DOI 10.1007/s00415-013-6873-7.
296. Scalfari A, Knappertz V, Cutter G, Goodin D, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis *Neurology* 2013; **81**(2):184-192. doi: 10.1212/WNL.0b013e31829a3388
297. DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC. The Role of Vitamin D in Nervous System Health and Disease. *Neuropathol Appl Neurobiol* 2013; **39**(5):458-484
298. Disanto G, Watson CT, Meier UC, Ebers GC, Giovannoni G, et al. Month of birth and thymic output. *JAMA Neurology* 2013; **70**(4):527-528
299. Reder AT, Goodin D, Ebers GC, Cutter G, Rametta M, Kremenchutzky M, et al. MS-Related Causes of Death and Clinical Outcomes in Patients from the 21-Year Long-Term Follow-up Study of Interferon Beta-1b. *Multiple Sclerosis Journal* 2013; **19**(5): 680-681
300. Galea I, Lederer C, Neuhaus A, Muraro PA, Scalfari A, Koch-Henriksen N, Heesen C, Koepke S, Stellmann P, Albrecht H, Winkelmann A, Weber F, Bahn E, Hauser M, Edan G, Ebers G, Daumer M. A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis. *European Journal of Neurology* 2013; **20**(7): 1107-1109
301. Handel AE, Sandve GK, Disanto G, Berlanga-Taylor AJ, Gallone G, Hanwell H, Drabløs F, Giovannoni G, Ebers GC, Ramagopalan SV. Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. *BMC medicine* 2013; **11**(1):163.
302. DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC. Review: the role of vitamin D in nervous system health and disease. *Neuropathology and applied neurobiology* 2013; **39**(5):458-484.
303. Disanto G, Vcelakova J, Pakpoor J, Elangovan RI, Sumnik Z, Ulmannova T, Ebers GC, Ramagopalan SV, Štechová K. DNA methylation in monozygotic quadruplets affected by type 1 diabetes. *Diabetologia* 2013; **56**(9):2093-2095.
304. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. The relationship between age, relapses and onset of progression in multiple sclerosis. *Multiple Sclerosis Journal* 2013; **19**(11):96
305. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Frequent early relapses don't always predict severe disability in multiple sclerosis. *Multiple Sclerosis Journal* 2013; **19**(11):336
306. Ebers GC. Interaction of environment and genes in multiple sclerosis. *Journal of the Neurological Sciences* 2013; **334**(1):161-163
307. Guimond C, Lee JD, Ramagopalan SV, Dymment D, Hanwell H, Giovannoni G, Criscuoli M, Yee IM, Vorobeychik G, Ebers GC, Sadovnick AD. Multiple sclerosis in the Iranian immigrant population of British Columbia, Canada: Prevalence and risk factors. *Multiple Sclerosis Journal* 2014; 1352458513519179
308. Ebers GC. MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No. *Multiple Sclerosis Journal* 2014; **20**(3):282-283.
309. Ebers GC. Epigenetics of MS. *Irish Journal of Medical Science* 2014; **183**:S78.
310. Sadovnick AD, Lee JD, Ramagopalan SV, Dymment DA, Hanwell H, Giovannoni G, Criscuoli M, Yee IM, Vorobeychik G, Ebers GC, Guimond C. Genetic and Environmental Risk Factors for Multiple Sclerosis among Iranian Immigrants in Canada. *Multiple Sclerosis Journal* 2014; **20**(7):909-910

311. Ebers GC. Epidemiology and Genetics of MS; what have we missed? *Multiple Sclerosis Journal* 2014; **20**(7):901.

BOOKS

1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Ebers GC, (eds.). *The Diagnosis of Multiple Sclerosis*. (1984) Thieme-Stratton. New York.
2. Paty DW, Ebers GC. *Multiple Sclerosis* (1998) F.A. Davis Co., Philadelphia.
3. Compston, DAS, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H. *McAlpine's Multiple Sclerosis*. (1998) Churchill Livingstone, div. of Harcourt Brace & Co. Ltd.

BOOK CHAPTERS

1. Ebers GC. CSF electrophoresis in MS. In "The Diagnosis of Multiple Sclerosis". Ed. Poser, CM (1984) Thieme-Stratton Inc., New York, pp 179-184.
 2. Ebers GC, Paty DW, Sears ES. Imaging in MS. In "The Diagnosis of Multiple Sclerosis". Ed. Poser, CM (1984) Thieme-Stratton Inc., New York, pp 185-201.
- Gorman E, Rudd A, Ebers GC. Giving the diagnosis of MS. In "The Diagnosis of Multiple Sclerosis". Ed. Poser, CM (1984) Thieme-Stratton Inc., New York, pp 216-222.
4. Ebers GC. Studies in MS: 1. Immunogenetics 2. CSF Studies in "The Immunology of MS" Research Monographs in Immunology. "Immunoregulatory Processes in Experimental Allergic Encephalomyelitis and MS."(1984) Elsevier Science Publishers pp233-256.
 5. Ebers GC. Multiple sclerosis and other demyelinating diseases. in "Diseases of the Nervous System". eds. A Asbury, G McKhann, I McDonald (1986) WB Saunders Company, Pennsylvania.
 6. Bulman DE, Pandey JP, Ebers GC. Gm allotypes in multiple sclerosis. In Cellular and Humoral Immunological Components of Cerebrospinal Fluid in Multiple Sclerosis. Ed. A Lowenthal and J Raus. New York, Plenum Publishing Corporation, 1987, pp 81-86.
 7. Weinshenker B, Bass B and Ebers GC. Studies of the natural history of multiple sclerosis. In: *Multiple Sclerosis*. Ed. Cazullo, (1987) pp 125-132.
 8. Ebers GC. Multiple Sclerosis. In: *Current Opinion in Neurology and Neurosurgery* (1988) 1(2):133-138. Gower Academic Journals, London, England.
 9. Ebers GC. Multiple Sclerosis. In: *Textbook of Internal Medicine*. Eds. WN Kelly, et al , JB Lippincott Company, Philadelphia 1989, pp 2395-2398.
 10. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Inter-rater variability on multiple sclerosis scales in a blinded, prospective clinical trial. In: *Recent advances in multiple sclerosis therapy*. eds. RE Gosette, P Delmotte. Elsevier Science Publishers (1989).
 11. Compston A, Ebers GC. The Genetics of Multiple Sclerosis. in: *Handbook of Multiple Sclerosis*, ed. S Cook, pub. Marcel Dekker, Inc. New York and Basel (1990) pp.25-40.
 12. Ebers GC. Multiple Sclerosis. In: *Textbook of Internal Medicine*. W.N. Kelly, et al eds., J.B. Lippincott Company, Philadelphia 1992 pp2168-2171.

13. Ebers GC. Lumbar puncture and CSF analysis. In: Textbook of Internal Medicine. W.N. Kelly, et al eds., J.B. Lippincott Company. Philadelphia (1992) pp 2259-2261.
14. Ebers GC. Diagnostic criteria and the early presentation of multiple sclerosis. Nuevas Perspectivas en el Diagnostico de la Esclerosis Multiple. Eds. MA Hernandez, O Fernandez. Junta Directiva de la Sociedad Espanola de Neurologia, Barcelona, December 1993. (published 1994)
15. Ebers GC. Genetic determinants of prognosis in multiple sclerosis. U.S. National Multiple Sclerosis Society. Annual MS Issues Forum 1994. (monograph)
16. Ebers GC. Immunogenetica E markers di suscettibilita nella sclerosi multipla. Proceedings of the Farmades Symposium (XII Updating course of the Italian Society of Neurology, (1994) pp 1-21.
17. Sadovnick AD, Ebers GC. Genetics of multiple sclerosis. Neurologic Clinics. JP Antel, guest editor. February 1995, pp 99-118.
18. Ebers GC, Dymont DA. Genetic and environmental factors. In: Sclerosi Multipla, Stato Dell'Arte. Eds. C Fieschi, G. Comi & C Pozzilli. Mosby Italia, Milan (1999), pp 3-8.
19. Rice G, Ebers GC. Multiple Sclerosis. In: Melman and Morrelli's Clinical Pharmacology, 4th Ed . (eds.) Carruthers SG, et al. 2000.
20. Dymont DA and Ebers GC (2003) Multiple Sclerosis (MS): Genetics. In: Cooper DN (ed.) Nature Encyclopedia of the Human Genome, vol. 4. London: Nature Publishing Group 2003: 175-178.
21. Ebers GC. Multiple sclerosis. In: Weber J (ed). Horizons in medicine 15. London: Royal College of Physicians, 2003: 65-72.
22. Sadovnick AD, Ebers GC. Multiple Sclerosis. P.A. Emery et al. Emery & Rimoins Principles and Practice of Medical Genetics. Philadelphia: Elsevier, Ltd., 5th edition, 2007, pp2851-2855
23. Filippini G and Ebers GC. Multiple sclerosis and optic neuritis, in "Evidence-based Neurology: Management of Neurological Disorders". Ed. Candelise L, et al. Blackwell Publishing Ltd, Oxford. 2007

LETTERS

1. Noseworthy, JH, Vandervoort MK, Ebers GC. Plasma exchange for MS (letter). Neurology (1990) 40(5):864-866.
2. Noseworthy JH, Vandervoort MK, Penman M, Ebers G, et al. Cyclophosphamide and plasma exchange in multiple sclerosis (letter) Lancet (1991) 338(8760):193-194
3. Noseworthy JH, Ebers GC, Roberts R. Cyclophosphamide and MS (letter; comment) Neurology (1994) 44:579-581.
4. Rice GP, Ebers GC. Ondansetron for intractable vertigo complicating acute brainstem disorders. (letter). Lancet (1995) 345(8958):1182-1183.
5. Ebers GC, Sadovnick AD. (letter to the editor). Re. GAMES issue. Journal of Neuroimmunology (2004 Aug); 153(1-2) 4-5.
6. Ebers GC, Sadovnick AD, Veith R. (letter to the editor). Re. Munger et al. Vitamin D intake and incidence of multiple sclerosis. Neurology (2004 (Sept); 63(5): 93
7. Petkau AJ, Ebers GC, Reder AT. (letter to the editor). Response to Deisenhammer and

Giovannoni to paper Longitudinal analyses of the effect of neutralizing antibodies etc. *Multiple Sclerosis* 2004; 10: 715

8. Sadovnick A, Yee I, Ebers GC. Birth order, infection in early life, and multiple sclerosis – Authors' reply. *Lancet Neurol* 2005; 4(12): 795.
9. Ebers, GC. Epstein-Barr virus infection and risk for MS – comment. *Journal Watch Neurology* 2006, 8(5): 35.
10. Ramagopalan SV, Dymont DA, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC. (letter to the editor). Re. Barcellos et al. Clustering of autoimmune diseases in families with a high risk for multiple sclerosis. *Lancet Neurology* (2007) (March); 6 (3):206-207
11. Ramagopalan SV, Anderson C, Sadovnick AD, Ebers GC, Matesanz F, Fernandez O, Alcina A, Chaudhuri A, Behan PO, Hafler DA, Compston A, Hauser SL; the International Multiple Sclerosis Genetics Consortium. Genomewide Study of Multiple Sclerosis. *New England Journal of Medicine* 2007 Nov 22;357(21):2199-2200
12. Ramagopalan SV, Dymont DA, Sadovnick AD, Ebers GC. HLA-DRB1 and multiple sclerosis in Malta. *Neurology* 2008;71:1379
13. Ramagopalan S, Dymont D, Ebers G. Autoimmune disease in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. *Multiple Sclerosis* 2008;14(9): 1288-1289
14. Ramagopalan SV, Dymont DA, Ebers GC, Sadovnick DA. Gestational Diabetes and multiple sclerosis. *Epidemiology* 2009;20(5):783-784
15. Ramagopalan et al. Mother-child blood group incompatibility and the risk of multiple sclerosis. *J Neurol* DOI 10.1007/s00415-009-5325-x. *Journal of Neurology* 2010;257(2)286 -287.
16. Guimond C, Dymont DA, Ramagopalan SV, Giovannoni G, Criscuoli M, Yee IM, Ebers GC, Sadovnick AD. Prevalence of MS in Iranian Immigrants to British Columbia, Canada. *Journal of Neurology* 2010;257:667-668
17. Ramagopalan SV, Dymont DA, Handunnetthi L, Rice GP, Ebers GC. A genome-wide scan of male sexual orientation. *J Hum Genet. Letter*
18. Ramagopalan SV, Sadovnick AD, Ebers GC, Giovannoni G. Letter to the editor: Effects of Infectious Mononucleosis and HLA-DRB1*15 in Multiple Sclerosis. *Mult Scler.* 2010; 16; 127-128.
19. Ramagopalan SV et al. Low Infant Sibling Exposure and Multiple Sclerosis. Gene-environment interaction. *Ann Neurol* 2010;67(5):694-695. Letter
20. Ramagopalan SV et al. Vitamin D–Dependent Rickets, HLA-DRB1, and the Risk of Multiple Sclerosis. *Arch Neurol* 2010;67(8):1034-1035. Research Letter.
21. George Ebers; Martin Daumer; Antonio Scalfari. Predicting a window of therapeutic opportunity in multiple sclerosis. *Brain* 2010; doi: 10.1093/brain/awq226.
22. Chao MJ et al. HLA B*44: Protective effects in MS susceptibility and MRI outcome measures. *Neurology* 2011 *Neurology* 77 (6):602-603.
23. Orton SM et al. Heritability of serum vitamin D concentrations: twin studies. *Am J Clin Nutr* 2011;93(3):667-668.

24. Ebers GC et al. Combined MRI lesions and relapses as a surrogate for Disability in MS. *Neurology* 2012;78:1367.
25. DiSanto G et al. Month of birth and thymic output. *JAMA Neurol* 2013;70(4):527-528

EDITORIALS

1. Ebers GC. Infections and demyelinating disease, editorial overview. *Current Opinion in Neurology & Neurosurgery*, (1992) 5(2) :173.
2. Ebers GC. Infections and demyelinating disease. Editorial Overview. *Current Opinion in Neurology & Neurosurgery*. (1993) 6(2):167-168.
3. Ebers GC. Multiple Sclerosis: New insights from old tools. (editorial) *Mayo Clinic Proceedings*. (1993) 68(7):711-2.
4. Kupersmith MJ, Kaufman D, Paty DW, Ebers G et al. Megadose corticosteroids in multiple sclerosis. *Neurology* (1994) 44(1):1-4.
5. Ebers GC. MRI: measure of efficacy. *Brain* 2000 123: 2187-2188.
6. Ebers GC. New diagnostic criteria for multiple sclerosis. *International MS Journal* 2001 8(3): 76-77.
7. Ebers GC. A twin consensus in MS. *Multiple Sclerosis*. *Multiple Sclerosis* (2005); 11: 497-499.
8. Ramagopalan SV, Ebers GC. Sequencing the multiple sclerosis genome: more questions than answers. *Lancet Neurology* 2010;9(8):757-759.
9. Ebers GC. Tasmania: state of MS in Australia *J Neurol Neurosurg Psychiatry* 2011;82:119.

PUBLICATIONS EDITED

1. Ebers GC. Infections and demyelinating disease. *Current Opinion In Neurology, Neurosurgery*. (April 1992) 5(2): 173-211. Edited by George C Ebers

ABSTRACTS

1. Ebers GC, Espinoza LR, Zabriskie JB. HLA-typing familial MS. *Can J Neurol Sci* (1976) 3:148.
2. Ebers GC, Fraser B, Van De Rign I, Zabriskie JB, Kunkel HG. Idiotypic determinants in SSPE. *Clin Res* (1977) 25:482A.
3. Ebers GC and Paty DW. The usefulness of isoelectric focusing in polyacrylamide gel (IEF-PAGE) in demonstrating oligoclonal banding in MS CSF. *Can J Neurol Sci* (1979) 6(3):396.
4. Ebers GC. Anti-idiotypic sera in the study of MS CSF IgG bands. *Ann Neurol* (1979) 104:1-3.
5. Ebers GC and Paty DW. Alkaline isoelectric focusing in polyacrylamide gel of MS CSF. *Ann Neurol* (1979).

6. Paty DW and Ebers GC. Clinical prognostic markers in multiple sclerosis. *Can J Neurol Sci* (1979) 6(3):38.
7. Ebers GC, Paty DW. Optic neuritis in multiple sclerosis families. Fifth Pan American Congress in Neurology (1979) Caracas, Venezuela.
8. Rice G, Ebers GC. Familial stroke syndrome associated with mitral valve prolapse. *Stroke* (1979) 10(1):97.
9. Ebers GC and Paty DW. Optic neuritis (O.N.) in familial MS. *Can J Neurol Sci* (1980) 7(4):332.
10. Feasby TE, Ebers GC, Paty DW and Fox A. Spinal cord swelling in multiple sclerosis. Canadian Congress of Neurological Sciences. (1980) Ottawa.
11. Ebers GC and Paty DW. Studies in familial MS. *Ann Neurol* (1980) 8:117.
12. Skanes VM, Barnard J, Drover S, Ebers GC et al. Allotypes of human C4. Eighth International Histocompatibility Workshop Conference Program (1980).
13. Ebers GC, Vinuela F, Feasby TE, Paty DW. Multifocal CT enhancement in MS. *American Academy of Neurology* (1980).
14. Ebers GC. Anti-idiotypic sera in the study of MS CSF bands-further studies. *American Academy of Neurology* (1980).
15. Noseworthy JH, Paty DW, Ebers GC. MS presenting in patients over 50 years of age. *American Academy of Neurology* (1980).
16. Salinas FA, Cousin HK, Ebers GC and Paty DW. Role of circulating immune complexes (CIC) in multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). *Can J Neurol Sci* (1981) 8(2):189.
17. Moulin D, Paty DW, Ebers GC. The predictive value of CSF electrophoresis in "possible" multiple sclerosis. *Can J Neurol Sci* (1981) 8(2):189.
18. Ebers GC, Vinuela F, Feasby TE, Paty DW. Multifocal CT enhancement in MS. *Can J Neurol Sci* (1981) 8 (2):190.
19. Ebers GC, Cripps J, Paty DW, Seland P, Nelson R. HLA typing in MS sibling pairs. *Can J Neurol Sci* (1981) 8(2):190.
20. Cripps JR, Ebers GC. MS - Evidence for an environmental effect. *Neurology* (1982) 32(2):A164.
21. Ebers GC. Osler and neurology. *Neurology* (1982) 32(2):A229.
22. Beckman J, Brown WF, Ebers GC. Dominant dystonia with bradykinesia and pseudomyotonia. *Neurology* (1982) 32(2):A113.
23. Feasby TE, Ebers GC. Risk of multiple sclerosis in isolated optic neuritis. *Can J Neurol Sci* (1982) 9(2):269.
24. Ebers G. Letter to the editor. *Arch Neurol* (1982) 39(2)
25. Ebers GC, Vinuela F, Feasby TE. Multifocal CT enhancement in MS. *Ann Neurol* (1982) 12:91-92.
26. Ebers GC, Paty DW, Moulin DW. The predictive value of CSF electrophoresis in "possible MS".

- Ann Neurol (1982) 12:104.
27. Ebers GC, Morton N, Paty DW. Segregation and linkage analysis of HLA typing in familial MS. *Neurology* (1983) 33 No.4 (2):180.
 28. Ebers GC, Farrell M, Kaufmann JC. Oligoclonal bands in MS: clinical pathological correlation. *Neurology* (1983) 33 No. 4 (2):141.
 29. Voulters L, Ebers GC, Armstrong H, Bass B. Agarose isoelectric focusing: an improved method for the detection of oligoclonal bands in MS. XVIII Canadian Congress, Nfld. (1983) 22-26.
 30. Makin GJV, Brown WF, Ebers GC. Scapular winging in C7 root lesions. *American Academy of Neurology*, (1984) Boston.
 31. Voulters L, Ebers GC. Agarose isoelectric focusing in CSF. *American Academy of Neurology*, (1984) Boston.
 32. Goodridge AE, Feasby TE, Ebers GC, Brown WF. Hand wasting in cervical spondylitic myelopathy. XIX Canadian Congress of Neurology, June 1984, Edmonton.
 33. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Gray T, Nelson R. A population based twin study in multiple sclerosis. *Am J Hum Genet* (1984) 36(4):49S.
 34. Hader WJ, Ebers GC. Multiple sclerosis in Canadian native people. *American Academy of Neurology*, (1985) Dallas, Texas. *Neurol.* 35(1) 300.
 35. Stoessl AJ, Brown J, Ebers GC. Multisegmental anhidrosis, tonic pupils and tendon hyporeflexia (Ross' syndrome). *Neurology* 35(1):243.
 36. Moulin DE, Foley KM, Ebers GC. Acute and chronic pain syndromes in multiple sclerosis (MS). *American Pain Society*, Dallas, Texas, Oct. 17-20, 1985.
 37. Beckett J, White BN, Simpson NE, Ebers GC, Holden J, MacLeod PM. X & Y chromosomes; human gene mapping by recombinant DNA techniques. *Human Gene Mapping Conference* (1985) Helsinki.
 38. Sadovnick AD, Ebers GC, Paty DW, Eisen K, Hashimoto SA, Hooge J. Causes of death in multiple sclerosis (1985) *Can J Neurol Sci* 12(2):189.
 39. Duquette P, Murray TJ, Pleines J, Ebers GC, Hader WJ, Meltzer C, Morris N, Sadovnick AD, Upton A, Warren S. Early onset multiple sclerosis: clinical profile in 477 patients. *Neurology* 35(Suppl. 1):198, 1985.
 40. Rice GPA, Ebers GC, Armstrong H, Paty DW. Absence of antibodies to HTLV I and HTLV III in sera of patients with multiple sclerosis and chronic myelopathy. 1986. *American Academy of Neurology*, New Orleans.
 41. Weinshenker B, Armstrong H, Ebers GC. A comparison of familial and sporadic MS. 1986. *American Academy of Neurology*, New Orleans.
 42. Ebers GC, Bulman D. The geography of MS reflects genetic susceptibility. 1986. *American Academy of Neurology*, New Orleans.
 43. Moulin DE, Foley KM, Ebers GC. Acute and chronic pain syndromes in multiple sclerosis (MS). 1986. *Canadian Congress of Neurological Sciences*, London, Canada

44. Bass B, Armstrong H, Ebers GC, Noseworthy J, Weinshenker B, Rice GPA. Significance of the single band in CSF protein electrophoresis. 1986 Can J Neurol Sci 13(2):169; abstract #32.
45. Weinshenker B, Bass B, Ebers GC. Studies of the natural history of multiple sclerosis. International Congress Virology and Immunology in Multiple Sclerosis: Rationale for Treatment. December 9-11, 1986, Milano, Italy.
46. Weinshenker B, Bass B, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: predictive value of the early clinical course. Neurology (1987) 37(Suppl 1):130.
47. Bass B, Weinshenker B, Rice GPA, Noseworthy J, Cameron MGP, Ebers GC. Tizanidine versus Baclofen in the treatment of spasticity in patients with multiple sclerosis: a double blind study. XXIInd Canadian Congress of Neurological Sciences, Vancouver, Canada, June 1987.
48. Feasby TE, Ebers GC, Fox AJ, Karlik S. Predictive tests in isolated optic neuritis. XXIInd Canadian Congress of Neurological Sciences, Vancouver, Canada, June 1987.
49. Weinshenker BG, Bass B, Ebers GC and Rice GPA. A preliminary clinical trial of Orthoclone OKT3 treatment in chronically progressive multiple sclerosis. Can J Neurol Sci 88: 15(2):196-197.
50. Ebers GC. Tissue plasminogen activator versus urokinase. The Lancet, October 29, 1988:1028 (letter).
51. Ebers GC, Bulman D, Sadovnick AD. Parent/child concordance in multiple sclerosis. American Society of Human Genetics, New Orleans, Louisiana, October 12-15, 1988. Am J Hum Genet 43(Suppl):A63, 1988.
52. Sadovnick AD, Paty DW, Ebers GC. Life expectancy and causes of death in multiple sclerosis. American Academy of Neurology, Chicago, Illinois, April 13-19, 1989. Neurology (1989) 39(Suppl 1):285.
53. D'Hooghe MB, Ebers GC. HLA in genetic susceptibility to multiple sclerosis: a recessive effect and the role of other genes. American Academy of Neurology, Chicago, Illinois, April 13-19, 1989.
54. D'Hooghe MB, Warshawski F, Ebers, G.C. Neurogenic pulmonary edema: brainstem localization of responsible lesions. American Academy of Neurology, Chicago, Illinois, April 13-19, 1989.
55. D'Hooghe MB, Ebers GC. A population-based study of seasonal onset of multiple sclerosis in London, Ontario. American Academy of Neurology, Chicago, Illinois, April 13-19, 1989.
56. Noseworthy JH, Vandervoort MK, Ebers GC, et al. Treatment preferences for patients with progressive multiple sclerosis (MS). American Academy of Neurology, Chicago, Illinois, April 13-19, 1989.
57. Ebers GC. The history of multiple sclerosis - a revision. American Osler Society Annual Meeting, Birmingham, Alabama, April 26-27, 1989.
58. Weinshenker BG, Hader W, Baskerville J, Ebers GC. The influence of pregnancy on disability from multiple sclerosis: a population based study in Middlesex County, Ontario. XXIVth Canadian Congress of Neurological Sciences. Ottawa, Canada, June 14-17, 1989.
59. Karlik SJ, Lee DH, Fox AJ, Noseworthy J, Ebers G, Szumowski J, Simon J. Water-suppressed MRI fails to detect lipid in MS lesions. American Society Neuroradiologists, 27th Annual Meeting, 1989.
60. Ebers GC. Twin studies in multiple sclerosis. XIVth World Congress of Neurology. New Delhi,

India. October 22-27, 1989.

61. Pringle CE, Hudson AJ, Ebers GC. Primary lateral sclerosis: the clinical and laboratory definition of a discrete syndrome. XXVth Canadian Congress of Neurological Sciences, Banff, Canada, June 27-30, 1990.
62. Noseworthy JH, Ebers GC, et al. Similarity of MRI behavior in "active" relapsing and progressive multiple sclerosis: results of a serial clinical-MRI study. XXVth Canadian Congress of Neurological Sciences, Banff, Canada, June 27-30, 1990.
63. Noseworthy JH, Ebers GC, et al. Clinical - MRI correlations in multiple sclerosis: a serial study using quantitative cranial and spinal MRI. XXVth Canadian Congress of Neurological Sciences, Banff, Canada, June 27-30, 1990.
64. Brownscombe I, Lapaucis A, Rice GPA, Ebers GC, Noseworthy, JH. Development of disease specific quality-of-life measure for multiple sclerosis. *Neurology* 40 (suppl):142, 1990.
65. Noseworthy JH, Lee D, Penman M, Hopkins M, Vandervoort MK, Karlik SJ, Rice GPA, Ebers GC. A Phase II Evaluation of Mitoxantrone in the treatment of progressive multiple sclerosis. American Academy of Neurology 43rd Annual Meeting, Boston, Mass. April 21-27, 1991
66. Walter MA, Gibson WT, Ebers GC, Cox DW. A susceptibility locus for multiple sclerosis lies within the immunoglobulin heavy chain variable region. *The American Journal of Human Genetics*.47(3), Abstract No. 0795, September 1990.
67. Hashimoto L, Mak TW, Ebers GC. T-cell receptor polymorphisms in MS. American Academy of Neurology 43rd annual meeting, Boston 1991.
68. Hudson AJ, Kiernan JA, Pringle CE, Munoz DG, Ebers GC. Comparative clinical and pathological changes in amyotrophic lateral sclerosis and primary lateral sclerosis. I.B.R.O. August 1991, Quebec City.
69. Hashimoto LL, Mak TW, Ebers GC. The role of major histocompatibility complex and T cell receptor genes (TCR) in MS susceptibility. 8th International Congress of Human Genetics. October 6-11, 1991, Washington, D.C. *Am J Hum Genet* (1991) 49(Suppl):481.
70. Noseworthy JH, Vandervoort MK, Ebers GC, Farquhar R, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, controlled multiple sclerosis clinical trial. American Academy of Neurology. May 3-9, 1992, San Diego, California. *Neurology* 42(Suppl 3):463
71. Casley WL, Abdalla JA, Armstrong HA, Hudson AJ, Ebers GC. Linkage studies in autosomal dominant myotonia congenita (Thomsen's Disease, ADMC). American Academy of Neurology. May 3-9, 1992, San Diego, California. *Neurology* (1992) 42(Suppl.3):282.
72. Abdalla JA, Armstrong HA, Brown JD, Ebers GC. Huntington's disease with a negative family history. American Academy of Neurology. May 3-9, 1992, San Diego, California. *Neurology* (1992) 42(Suppl.3):472.
73. Noseworthy JH, Vandervoort MK, Ebers GC, Farquhar R, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, controlled multiple sclerosis clinical trial. *Neurology* (1992):42(Suppl 3):463.
74. Claudio JO, Figlewicz DA, Farlow MR, Harper P, MacMillan JC, Boustany R, Kolodny EH, Ebers GC, Rouleau GA. Genetic linkage mapping of hereditary spastic paraplegia. American Society of Human Genetics, 1992
75. Brown WF, Watson BV, Garland J, Ebers GC, Desai N. Diaphragmatic dysfunction in multiple

- sclerosis. *Ann Neurol* 1992;32(No.2):295.
76. Sadovnick AD, Ebers GC. A population based twin study in multiple sclerosis. *Am Soc Hum Gen 1992 mtg -San Francisco. Am J Hum Genet (1992):51(Suppl A26)*
 77. George AL, Crackower MA, Abdalla J, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease. *Works in Progress, American Academy of Neurology 45th Annual Meeting, April 25-May 1, 1993, New York NY.*
 78. Weinshenker BG, Baskerville J, Ebers GC. Identifying suitable candidates for clinical trials of progressive MS. *118TH American Neurological Association meeting. Boston, Mass. October 18-20, 1993*
 79. Hashimoto LL, Ebers GC, Bell RB. Villin/BCG polymorphisms in multiple sclerosis susceptibility. *World Federation of Neurology Satellite Symposium on Multiple Sclerosis. Victoria, BC, September 11-14, 1993.*
 80. Ebers GC. Genetics and multiple sclerosis: Overview. *World Federation of Neurology Satellite Symposium on Multiple Sclerosis. Victoria, B.C. Sept. 11, 1993.*
 81. Sumner SM, Ebers GC. Multiple sclerosis susceptibility and the tumor necrosis factors. *American Society of Human Genetics. 43rd Annual Meeting, October 5-9, 1993, New Orleans, LA. A.J. Hum Genet (1993) 53 (Suppl):1086.*
 82. Trejo V, Ollier W, Silman A, Ebers G, Derom R, Derom C, Vlietinck R, Gregersen PK. X chromosome inactivation patterns in female monozygotic (MZ) twins. *American Society of Human Genetics 43rd Annual Meeting, October 5-9, 1993, New Orleans, LA. Am J Hum Genet (1993) 53(Suppl):656.*
 83. Graffagnino C, Maher, Quinones A, Hachinski V, Friedman A, Ebers GC, Ferguson GG, Drake CG, Roses AD, Alberts MJ. Genetic aspects of Intracranial aneurysms and SAH. *19th International Joint Conf. on Stroke and Cerebral Circulation. San Diego, Calif. Feb. 17-19, 1994.*
 84. Sadovnick AD, Greenberg C, Bourque C, Ebers GC. Multiple sclerosis in descendants of a mating between "ethnically" resistant (Amerindian) and susceptible (Scottish) individuals. *Canadian Congress of Neurological Sciences, Toronto, June 1993. Can J Neurol Sci 20 (Suppl.2):557, 1993.*
 85. Sadovnick AD, Ebers GC, Risch N. Canadian collaborative project on genetic susceptibility to multiple sclerosis. *Canadian Congress of Neurological Sciences, Saint John's, Newfoundland. June 27-30, 1994.*
 86. Sadovnick AD, Ebers GC, Risch N. Genetic susceptibility to multiple sclerosis: A Canadian collaborative study of over 20,000 patients. *Multiple Sclerosis Medical Satellite Symposium. Budapest, Hungary. Sept. 17-19, 1994.*
 87. Zeesman S, Whelan DT, Pringle CE, Ebers G, Bulman DE. The infantile form of olivopontocerebellar atrophy type III: an example of anticipation and paternal effect. *American Society of Human Genetics, Montreal, October 18-22, 1994.*
 88. Murray JD, Bulman DE, Ebers GC, Lathrop GM, Rice GPA. Linkage of morbid obesity with polymorphic microsatellite markers on chromosome 1q31 in a three-generation Canadian kindred. *American Society of Human Genetics, Montreal, October 18-22, 1994.*
 89. Figlewicz DA, Dube M-P, Farlow MR, Ebers GC, Harper P, Kolodny EH, Baumbach L, Rouleau GA. Autosomal dominant familial spastic paraplegia: Linkage analysis and evidence for linkage to chromosome 2p. *American Society of Human Genetics, Montreal, October 18-22, 1994. Am J*

- Human Genet 55(3)(Suppl.):1071.
90. Murray JD, Bulman DE, Ebers GC, Lathrop M, Rice GPA. Autosomal dominant obesity susceptibility, a linkage analysis study in an Ontario family. IBC's First International Symposium: Obesity: Advances in Understanding and Treatment. Washington, DC, Feb. 27-March 1, 1995.
 91. Ebers GC, Sibley WA, Paty DW and the IFNB Study Group. Immunotherapy for multiple sclerosis: Clinical aspects and trials. *Acta Neurol Scand* (1995) 91(Suppl 161): 54.
 92. McLachlan RS, Maher J, Bulman D, Racacho L and Ebers GC. Genetic studies of febrile convulsions in selected families. 21st International Epilepsy Congress, Sydney, Australia. September 3-8, 1995.
 93. Rice G, Dickey C, Lesaux J, Vandervoort P, MacEwan L, Ebers G. Ondansetron for disabling tremor in multiple sclerosis. 120th Annual Meeting of the American Neurological Association.
 94. Dubé M-P, Mlodzienski MA, Kibaar Z, Farlow MR, Ebers G, Harper P, Kolodny EH, rouleau GA, Figlewicz DA. Hereditary spastic paraplegia: lod score considerations for confirmation of linkage in an heterogeneous trait. *Am J Hum Genet* 1996 59(4) (Suppl): 1243
 95. Sadovnick, AD, Yee IML, Ebers GC. Co-variates influencing sib risks in multiple sclerosis. *Am J Hum Genet* 1997 61(4) (suppl.):1106.
 96. Bulman DE, van Oene MD, Hahn AF, Tollar LL, Ebers GC. A novel sodium channel mutation causing hypokalemic periodic paralysis. *Am J Hum Genet* 1997 61(4) (suppl.):1914.
 97. Ebers GC, Oger J, Paty D et al. The Multiple Sclerosis PRISMS Study: Prevention of relapses and disability by interferon β -1a subcutaneously in multiple sclerosis. *Ann Neurol* 1997 42(6):986.
 98. Murray J, Noble-Topham S, Ebers GC. General principles of linkage analysis. 8th International Headache Research Seminar: Genetics of Headache Disorders, Nov 1997, Copenhagen, Denmark.
 99. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC & the North American Linomide Trialists. Phase 3 North American trial of roquinimex (Linomide) in relapsing-remitting and secondary progressive multiple sclerosis (MS): Clinical results. *AAN* (submitted) Minneapolis Minnesota, April 25-May 2, 1998.
 100. Ganapathy R, Noble-Topham S, Mandalfino P, Ebers GC. Familial migraine with aura is not linked to documented FHM loci in four Canadian multiplex kindreds. *Am J Hum Genet* (1998) 63(4)(Suppl):1672.
 101. Ebers, G.: A meta-analysis of genomic screens in multiple sclerosis. The transatlantic Multiple Sclerosis Genetics Cooperative. *Multiple Sclerosis* 2001, 7:3-11.
 102. Wingerchuk DM, Kremenchutzky M, Rice GPA, Ebers GC. How many patients with Multiple Sclerosis are ever eligible for Therapeutic Trials? American Neurological Association. October 2000.
 103. Ebers GC. The Natural History of Multiple Sclerosis. *Neurological Sciences* (2000)21:S815-S817.
 104. Wingerchuk DM, Lesaux J, Rice PA, Lee D, Kremenchutzky D, Ebers GC. A pilot study of oral calcitriol (vitamin D3) for relapsing-remitting multiple sclerosis (RRMS). 17th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dublin, Ireland Sept 12-15, 2001. *Mult Scler* 2001;7(Suppl 1):S67.
 105. Dymnt D.A., Datta, A., Armstrong H., Canadian Collaborative Study Group, Sadovnick, A.D.,

- Risch, N., Hader W., Ebers, G.C. Genomic screen for multiple sclerosis susceptibility genes in Hutterite families. Presented at MS 2000, Banff, Alberta, Canada. Published in Meeting Proceedings.
106. Sadovnick, A.D., Ebers, G.C., Risch, N. and the Canadian Collaborative Study Group. The Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis. Presented at MS 2000, Banff, Alberta, Canada. Published in Meeting Proceedings.
 107. Willer, C.J., Dyment, D.A., Sadovnick, A.D., Risch, N., Ebers, G.C. and the Canadian Collaborative Study Group. Concordance in twin pairs with MS is not influenced by the presence of the HLA-DRB1*1501 allele. Presented at MS 2000, Banff, Alberta, Canada. Published in Meeting Proceedings.
 108. Willer, C.J., Holmes, R., Yee, I., Dyment, D., Risch, N., Sadovnick, A.D., Ebers, G.C. The Canadian Collaborative Study of twins with multiple sclerosis. (ABSTRACT). Accepted for presentation at the American Society of Human Genetics, San Diego, October, 2001. *Amer. J. Hum. Genet.* 69(4): 386, 2001
 109. Sadovnick, A.D., Risch, N.J., Ebers, G.C. and the Canadian Collaborative Study Group. Multicentre Studies in MS: The Canadian Experience ABSTRACT. Platform presentation, 2nd International MS Week, Consortium of MS Clinics, Chicago, June, 2002. *Int. J. MS Care* 2002;4:77.
 110. Ebers GC, Sadovnick D, Risch N. Insights into the genetics of MS from the Canadian Collaborative Project. (ABSTRACT). Presented at ECTRIMS/ACTRIMS, September 2002, Baltimore. *Multiple Sclerosis* 2002; 8(Suppl 1):S18.
 111. Sadovnick D, Ebers G, Dyment DA on behalf of the Canadian Collaborative Study Group. MS in step-siblings: recurrence risk and ascertainment. (ABSTRACT) ECTRIMS, September 2004, Vienna. *Multiple Sclerosis* 2004; 10(supplement 2):S162 (awarded ECTRIMS poster prize).
 112. Herrera BM, Armstrong H, Dyment D, Cader Z, DeLuca GC, Lincoln MR, Orton S, Willer C, Morrison K, Ebers GC. A Comprehensive Search for Susceptibility to MS on the X-Chromosome (ABSTRACT). Presented at the ASHG, Toronto, October 2004.
 113. Herrera BM, Lincoln MR, Ebers GC. Parent of origin effect in multiple sclerosis. (ABSTRACT). Presented at Genomic Development and Disease Meeting, St. Catherine's College, Oxford, April 2005.
 114. Sadovnick AD, Yee I, Ebers GC. Birth Order in Multiple Sclerosis: Canadian Data (ABSTRACT) ECTRIMS, September 2005, Thessaloniki, Greece.
 115. Herrera BM, Cader MZ, Lincoln MR, Ramagopalan S, Orton S, Dyment DA, Tzenova J, Ebers GC. Follow up investigation of twelve proposed linkage regions in Multiple Sclerosis (ABSTRACT). ASHG, Salt Lake City, October 2005.
 116. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar J, Ferretti V, Tienari PJ, Risch NJ, Sadovnick AD, Peltonen L, Ebers GC, Hudson TJ. MHC association in multiple sclerosis is restricted to the HLA class II region by dense SNP mapping (ABSTRACT) ASHG, Salt Lake City, October 2005.
 117. Ebers et al. Immunomodulation: The IFNB-1b long term follow-up study: predictive clinical and MRI markers. ECTRIMS. Prague 2007
 118. Ebers GC et al. Expression of the Multiple Sclerosis associated MHC Class II allele HLA-DRB1*1501 is Regulated by Vitamin D. Presented at ANA meeting Salt Lake City, September 2008

June 1982

14. MS - Environment vs Genetics Notre Dame Hospital, University of Montreal, Montreal, Quebec
January 1982
15. MS: nature or nurture Neuroscience Seminar, Queen's University, Kingston, Ontario
February 1982
16. HLA and MS Dept of Immunology, Memorial University, St. John's, Nfld.
February 1982
17. Idiotypes in MS Memorial University, Dept. of Immunology, St. John's, Nfld.
February 1982
18. The Genetics of MS Rockefeller University, Dept. of Immunology, New York, NY
April 1982
19. The Immunology of MS CSF Cornell Medical Center, New York Hospital, New York, NY
April 1982
20. Genetics vs Environment in MS Cornell Medical Center, New York Hospital, New York, NY
April 1982
21. Diagnostic Criteria in MS - The Diagnosis of MS, Washington DC
April 1982
22. The Immunogenetics of MS University of Louvain, Brussels, Belgium
February 1983
23. Idiotypes in MS University of Louvain, Brussels, Belgium
February 1983
24. HLA and MS Laboratory of Jean Dausset, Hospital St. Louis, Paris, France
February 1983
25. Sib Pair Analysis in MS Laboratory of Jean Dausset, Hospital St. Louis, Paris, France
February 1983
26. Immunology of MS International Federation of Multiple Sclerosis Societies,
Vancouver, B.C. September 1983
27. Oligoclonal Bands in MS New York Academy of Science, Symposium on MS, New York,
NY December 1983
28. Immunogenetics of MS Cornell University Medical Center Symposium, New York, NY
December 1983
29. Genetic Factors in MS Rockefeller University, New York, NY December 1983
30. The Genetics of MS Workshop on the Genetics of MS, CIBA House, London,
England January 1984
31. The Genetics of MS Welsh National School of Medicine, Cardiff, Wales
January 1984
32. The Nature of MS Susceptibility Emory University, Atlanta, Georgia

			April 1984
33.	Osler and Neurology	American Osler Society, Atlanta, Georgia	April 1984
34.	Osler and MS	Oslerfest, Oxford, England	September 1984
35.	The Genetics of MS	World Federation of Neurology, Hamburg	Satellite Symposium - MS September 1985
36.	Genetic Factors in MS	The MS Societies of Great Britain & Northern Ireland National Hospital, Queen Square, London, England	September 1985
37.	Genetics of MS	Asilomar Conference, National U.S. MS Society, California	November 1985
38.	Gm Allotyes and MS	International Federation of MS Societies, NATO Symposium on Advanced Research, Belgium	April 1986
39.	MS - Nature or Nurture	University of Pennsylvania, Philadelphia, PA	May 1986
40.	Prognosis in M.S.	University of Pennsylvania, Philadelphia, PA	May 1986
41.	Prognostic Factors in MS	Association of Life Insurance Medical Directors of America, Ottawa, Ontario	October 1986
42.	Genetic Studies in MS	University of Texas, Department of Neurology, Dallas, Texas	October 1986
43.	Osler and Neurology	University of Texas, Department of Neurology, Dallas, Texas	October 1986
44.	Recent Advances in MS	North Texas Chapter, Multiple Sclerosis Society, Dallas, Texas	October 1986
45.	Prognosis in MS Immunology in MS, University of Milan, Milan, Italy	Rationale for Treatment International Congress, Virology & Immunology in MS, University of Milan, Milan, Italy	December 1986
46.	Genetics & Epidemiology of MS	University of Liverpool, Department of Neurology & Medical School, Liverpool, UK	April 1987
47.	Genetics of MS	John Radcliffe Infirmary, Department of Neurology, Oxford University, Oxford, UK	April 1987
48.	Genetics of MS	John Radcliffe Hospital, Department of Molecular Hematology, Headington, Oxford, UK	April 1987
49.	Genetics of MS London, UK	National Hospital for Nervous Diseases, Queen Square, London, UK	June 1987
50.	Discussant	Board of MS Society of Great Britain & Northern Ireland, Royal	

- Society of Medicine, London, U.K. June 1987
51. Genetics of MS Max Planck Institute for Studies in Demyelinating Disease, Wurzburg, Germany
 52. Prognosis in MS Welsh National School of Medicine, Cardiff, Wales
August 1987
 53. Natural History of MS 5th ECTRIMS Congress, European Committee for Treatment & Research in MS, Brussels, Belgium March 1989
 54. Genetics & MS University of Alabama, Birmingham, Alabama
April 1989
 55. Genes and Susceptibility to MS Workshop Chairman, National MS Society(USA), Cambridge, UK
July 1989
 56. Clinics of MS Karolinska Institutet, Stockholm, Sweden
October 1989
 57. 14th World Congress of Neurology International Federation of MS Societies
New Delhi, India October 1989
 58. IFFMSS, Inaugural Pringle Lectureship & Recipient of Pringle Medal, Dublin, Ireland
October 1990
 59. Visiting Professor University of British Columbia, Vancouver, BC
December 1990
 60. Genetic Epidemiology Jefferson University, Philadelphia, PA January 1991
 61. Genetic Epidemiology of MS University of Minnesota, (Visiting Professor), Minneapolis, Minnesota
April 1991
 62. Natural History & Therapeutic Trials for MS University of Minnesota, Clinical Neuroscience Conference, Minneapolis, Minnesota April 1991
 63. Foreign lectureship Neurologic Society of Norway May 1991
 64. Genetics of Multiple of MS Mini-symposium
Finnish MS Society, Turku, Finland. May 1991
 65. Localisation of the Gene for Paramyotonia Congenital Karolinska Institutet, Huddinge, Sweden
May 1991
 66. Immunogenetics of MS The 1991 J. Allyn Taylor International Prize in Medicine Symposium on Regulation of Autoimmunity
November 1991
 67. Genetics of MS Cambridge University, Cambridge, U.K.
 68. MS: an overview Karolinska Institutet, Huddinge, Sweden
January 1992
 69. Linkage Study of MS Institute of Molecular Medicine, Oxford, UK

- September 1992
70. Argentina Neurological Society Foreign Speaker
Buenos Aires October 1992
71. 2nd WEHI Research Meeting - Progress in MS Research
Walter & Eliza Hall Institute of Medical Research, Melbourne,
Australia November 1992
72. 1. Natural History of MS ; 2. History of MS; 3. Genetic Epidemiology of MS
Department of Neurology, University of Auckland, New Zealand
November 1992
73. Genetic Epidemiology of MS Dept. of Neurology, Mayo Clinic, Rochester, Minnesota
September 1993
74. MS Conference - MS Research Update
MS Society of Canada, Saskatchewan Division, Saskatoon, SK
October 1993
75. 1. MS as a Polygenic Disease; 2. Molecular Genetics & Epidemiology
Wayne State University, Grand Rounds, Neurology, Detroit,
Michigan November 1993
76. Neuroinflammatory Diseases: 1. Natural History of MS; 2. Design & Interpretation of Clinical
Trials in MS; 3. Genetic Epidemiology of MS
Karolinska Institutet, Dept. Of Neurology, Huddinge, Sweden
November 1993
77. 1. Early Diagnosis in MS The Multiple Sclerosis Group of the Spanish Neurology Society
2. Prognosis of MS Barcelona, Spain December 1993
78. Genetic Epidemiology of MS University of Maryland, School of Medicine, Baltimore, MD
April 1994
79. Prognosis in MS "Genetic Determinants of Disease Outcome" MS Issues Forum,
Washington, D.C. May 1994
80. Multiple Sclerosis as a Complex Trait
Royal College Speaker, Canadian Congress of Neurological
Sciences, St. John's, Nfld. June 1994
81. 1. Neuroimmunology: Immune Mechanisms, Interactions & Therapeutic Strategies
2. MS: Natural History of the Disease
Neurological Society of Rosario, Neurological Society of
Argentina August 1994
82. New Treatment Perspectives in MS
Centre for Advanced Study, University of Bergen, Oslo, Norway
September 1994
83. Immunotherapy for MS: clinical aspects and trials
Update Europe, Vienna, Austria September 1994
84. Immunotherapy for MS: clinical aspects & trials
National MS Society of Australia, Canberra, Australia
September 1994

85. Immunogenetics & Susceptibility Markers in MS
Fourth International Congress, International Society
of Neuroimmunology, "A Dale McFarlin Memorial in MS",
Amsterdam October 1994
86. MS: An Updating on Diagnosis & Therapy "Immunogenetics & Susceptibility Markers in MS"
XII Corso di Aggiornamento della Societa Italiana di Neurologia
Bari, Italy October 1994
87. MS as a Complex Trait: genes & environment
Queen's University, Kingston, Ontario October 1994
88. Complex Traits: genetic epidemiology & molecular genetics
Allyn Taylor International Prize in Medicine Symposium: "The
Genetic Basis of Neurological Disorders", University Hospital,
London, Ontario November 1994
89. New Directions: management of MS
Berlex Grand Rounds, Health Science Communications
Duke University, North Carolina February 1995
90. 1. CSF in the Diagnosis of Neurological Disorders; 2. Introduction to Molecular Genetics;
3. Immunotherapy of MS; 4. Molecular Genetics of Neuromuscular Disorders; 5. Molecular
Genetics of the Dementias; 6. Complex Traits: Epidemiology and Genetics in MS
Alfred Grendel Trust Visiting Professorship, Auckland Hospital, Auckland, New Zealand
February 1995
91. International Symposium, The Banbury Center "Genetics of Human Behaviour"
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
March 1995
92. Oslo International Think-tank on MS Epidemiology
Chairman-Genetics Session, Centre for Advanced Study at the Norwegian Academy of Science &
Letters, Norway June 1995
93. Workshop on the Epidemiology & Genetics of MS
Alghero, Sardinia June 1995
94. Workshop on Genetic Models for MS & Related Disorders
Chairman - Future Directions,
National MS Society (USA), Quebec City, QC
August 1995
95. Genetic Susceptibility in MS 11th European Congress on MS, (ECTRIMS), Jerusalem, Israel
September 1995
96. Genetics of MS Schering AG, Berlin, Germany October 1995
97. Genetic Epidemiology of MS IX PAN AM Congress of Neurology, Guatemala
October 1995
98. MS as a Complex Trait Workshop on Genetic Factors in MS MS Forum, PPS Europe
Ltd, Boston, MA October 1995
99. 1. Genetics of Movement Disorders; 2. Genetics of MS; 3. MS: Natural History; 4. Genetics of
Neuromuscular Disorders II Congreso Nacional de Neurologia, Barranquilla, Columbia

- November 1995
100. The Nature & Nurture of MS Susceptibility
The McEwan Professorship & Lecture, University of Toronto, Toronto, Canada
November 1995
 101. The Natural & Unnatural History of MS:Neurology Research Day,
University of Toronto, Toronto, Canada
November 1995
 102. Demyelinating Diseases & Infections in the Nervous System
Karolinska Institutet, Division of Neurology, Huddinge, Sweden
November 1995
 103. MS Genetics . Karolinska Hospital, Molecular Medicine Unit, Stockholm, Sweden
November 1995
 104. Observations on the Pathogenesis of MS
University of Calgary, CNS Grand Rounds Calgary, AB
November 1995
 105. Genetics of MS
The New York Hospital, Cornell Medical Center, Neurology, Neurosurgery & Radiology
Grand Rounds, New York, NY
December 1995
 106. New Directions in the Management of MS
Grand Rounds, University of Arkansas, College of Medicine,
Little Rock, AR
February 1996
 107. Genetics of MS
Atlanta, GA
Advances in MS Conference, Cambridge Healthtech Institute,
April 1996
 108. Inclusion & Exclusion Criteria for MS Trials
Sixth Modern Management Workshop, "Design
& Interpretation of Clinical Trials in MS",
Stockholm, Sweden
April 1996
 109. Genetics of Multiple Sclerosis
13th Meeting on Neuro-transmitters & Disease
Shinjyuku, Tokyo, Japan
June 1996
 110. 1. Current Understanding of the Pathogenesis & Natural History of MS; 2. The History of a
Disease: Multiple Sclerosis - approaches to the history of neuroscience; 3. Multiple Sclerosis - an
example of a complex genetic trait
Neurobiology Review Course Genetic Diseases of the Nervous
System, Canadian Congress of Neurological Sciences London,
Canada
June 1996
 111. The Genetics of MS
University of Oxford, John Radcliffe Hospital, Oxford, UK
September 1996
 112. MS Clinical Trials: a critical overview
University of Oxford, John Radcliffe Hospital, Oxford, UK
September 1996
 113. Strategies to Identify MS Genes
ECTRIMS, 12th European Congress on MS, Copenhagen, Denmark
September 1996
 114. Complex Traits in Neurology
Cornell University Medical College, New York, NY

- October 1996
115. Guidelines for Treatment Toronto Neurology Update November 1996
116. Genetic Susceptibility & Environmental Factors: the Canadian experience
ARSEP-MS Research Society, Paris, France
December 1996
117. The Pathogenesis of MS & New Treatments
Hotel Dieu Grace Hospital, Department of CNS, Windsor, ON
December 1996
118. MS Nature vs Nurture Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Toronto, ON January 1997
119. Trials on Trial (Overview) Controversies in the Management of Relapsing MS –
Symposium, Kananaskis, AB March 1997
120. Techniques & Clinical Implications of Imaging in MS MS Forum - Workshop,
Aylesbury, UK April 1997
121. Dissecting a Complex Trait 3rd International Symposium -The Molecular Biology of
the Nervous System, Toronto, ON. June 1997
122. Genetic Susceptibility in MS 17th Blankenese conference,
Hamburg, Germany June 1997
123. 1. Issues in Diagnosis, Classification & Prognosis; 2. Lessons from Recent Clinical Trials
Conference - MS Clinical Issues & Decisions,
Toronto, ON August 1997
124. Genetic & Environmental Basis of Multiple Sclerosis Susceptibility
Gordon Research Conference, "Molecular Human Genetics",
Rhode Island August 1997
125. Genetic Studies in MS XVI World Congress of Neurology, Buenos Aires, Argentina
September 1997
126. Genetics International Federation of MS Societies, Post-Congress
Symposium "Multiple Sclerosis", Buenos Aires, Argentina
September 1997
127. Genetics of MS International Federation of MS Societies, Workshop on the
Genetics of MS, Madrid, Spain October 1997
128. Familial MS 13th Congress of the European Committee for Treatment &
Research in MS, Istanbul, Turkey November 1997
129. Multiple Sclerosis: CPP-income security
Programs-Disability Unit, Human Resources Development,
London Convention Centre, London, ON
March 1998
130. Genetics : physiopathy of multiple sclerosis course
Update in Clinical Neurology, Universities of Milan, Pavia, Rome
& Messina, Italy March 1998

131. Modern Management MS Forum & Workshop, Executive Committee, Lisbon, Portugal
March 1998
132. Recent Advances in the Treatment of MS
Canadian Congress of Neurological Sciences, Montreal, Quebec
June 1998
133. Prognosis for People with MS
MS Forum Symposium, ECTRIMS, Stockholm, Sweden
September 1998
134. The Genetics of MS: clinical & scientific applications
MS Forum Symposium, ECTRIMS, Stockholm, Sweden
September 1998
135. Betaseron : results of the European Study in Secondary Progressive Multiple Sclerosis
Schering Satellite Symposium, Stockholm, Sweden
September 1998
136. The Role of Environmental Factors in MS: introduction
10th MS Forum Workshop, Montreal, Canada
October 1998
137. Other Environmental Factors and their Influence on MS
10th MS Forum Workshop, Montreal, Canada
October 1998
138. Genetics of MS Symposium on Multiple Sclerosis; new dimensions in basic research & their
clinical applications Philadelphia, USA November 1998
139. Research/Medical Update MS Society, Ontario Division Conference, Toronto, Canada
November 1998
140. Industry/Academic Collaborations and the Olivieri Case
Berlex Grand Rounds, Mississauga General Hospital,
Mississauga, Canada November 1998
141. A Critique of MR as a Measure of Pathology in MS
Serono International Symposium - Use of Imaging & Other
Monitoring Measurements in Multiple Sclerosis Treatment
strategies, Santa Fe, USA November 1998
142. Interferon Beta: Current and Future Use
Serono International Symposium - Use of Imaging & Other Monitoring Measurements in Multiple
Sclerosis Treatment Strategies, Santa Fe, USA November 1998
143. Effect of Beta Interferon on Immune Modulation and Natural History
11th Modern Management Workshop of the MS Forum, Venice, Italy March 1999
144. Epidemiology of MS Regional North American Annual Meeting of the World
Federation of Neuroepidemiology, Research Group on Neuroepidemiology, Toronto, Canada
April 1999
145. The Unnatural History of Multiple Sclerosis

Royal College of Physicians and Surgeons, Dublin, Ireland
May 1999

146. Review of Recent Clinical Trials in MS and The Natural History of Relapsing-remitting and Secondary-progressive MS Australian Association of Neurologists, Hobart, Tasmania, Australia May 1999
- Natural History of Multiple Sclerosis: the role of MRI as a surrogate outcome measure in multiple sclerosis Meeting: Washington DC November 1999
148. Osler's Contributions to Neurology The Osler Club of London November 1999
149. Natural History of Multiple Sclerosis Institute of Neurology, University College, London January 2000
150. Chair, Meeting UK Glial Cell Club, Brunel University, London January 2000
151. Pathogenesis of Multiple Sclerosis
5th Annual Millennium Meeting, Medical Ophthalmological Society, Royal Hallamshire Hospital, Sheffield February 2000
152. Prognostic Factors in Multiple Sclerosis Gallarate, Italy March 2000
153. Relapse Frequency in the First Years Related to Outcome: a 25-years follow-up study in Canadian MS patients European Charcot Foundation Symposium March 2000
154. How to Assess Prognosis and its Modification in Chronic Neurological Disease
Neurology for Neuroscientists VI, Oxford March 2000
155. Interferons and Glatiramer Acetate in the Treatment of Relapsing Remitting and Secondary Progressive Multiple Sclerosis (Do they prevent the progression of the disease?).
International Symposium on Multiple Sclerosis, Aula Magna of the University, Palazzo Renata di Francia, Italy April 2000
156. Benefits & Drawbacks of Longitudinal Data Collection Over the Methodology Commonly Used in Clinical Trials
International Workshop on Longitudinal Data Collection in MS, Cairns, Australia May 2000
157. The Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis AstraZeneca, Sweden August 2000
158. Genetics 1st ESNI Course, Stockholm September 2000
159. Observations of the progressive phase of MS Italian Society of Neurology, Milan September 2000
160. The Natural History of MS Across MS Frontiers, The Netherlands October 2000
161. Natural History of MS 1st Congress of LACTRIMS, Buenos Aires November 2000
162. The Genetics of MS Midland Neurological Society, Coventry

November 2000

163. Assessment of Randomized Clinical Trials in Chronic Variable Disease
West London Neuroscience Centre November 2000
164. Epidemiology of Multiple Sclerosis
Scottish Multiple Sclerosis Symposium, St. Andrews
December 2000
165. Natural History and Genetics of MS
Conquering MS, Research in Canada in the New Millennium, Banff, Canada
December 2000
166. Observations on the Natural History of Multiple Sclerosis
Postgraduate Centre, Hope Hospital, Salford
January 2001
167. Genetics of Multiple Sclerosis Neurology for Neuroscientists, Magdalen College, Oxford
March 2001
168. Clinical Trials in Multiple Sclerosis: a critical analysis
Pharmaceutical & Biotechnology Team Multiple Sclerosis Conference, London
April 2001
169. Multiple Sclerosis – The Genetics of MS
Joint Meeting of ABN and Norwegian Society, Oslo, Norway
May 2001
170. The Natural History of MS Observations from 25,000 Patient Years of Follow-up
Tokyo, Japan May 2001
171. Epidemiology & Genetics of MS
University College, London May 2001
172. The Non-genetic Part of MS Susceptibility: multiple sclerosis 2001, a new era in research and
therapeutics New Jersey Medical School, USA May 2001
173. Natural History of MS Canadian Congress of Neurological Sciences
June 2001
174. Lessons from the Natural History of Multiple Sclerosis
Congress of Epidemiology, Toronto, Canada
June 2001
175. Autosomal Dominant Episodic Vertigo
Inaugural Meeting of the British Society of Neuro-Otology, MRC, London
June 2001
176. CPC: Clinical presentation XVII World Congress of Neurology, London
June 2001
177. MS and/or Migraine CFBS Genetics Symposium , Ottawa, Canada
June 2001
178. Immunogenetics of Autoimmune Disease
11th International Congress of Immunology, Stockholm

- July 2001
179. Advancing Therapies for MS Advisory Panel for CNS Medical Group, Bermuda
July 2001
180. Heeding the Lessons of Natural History: the importance of attacks in disease progression
Biogen Canada, Parameters of Efficacy in MS: Optimizing
the use of Interferons, Niagara, Canada
August 2001
181. Immunogenetics: what can it tell us?
VIth International Congress of Neuroimmunology, Edinburgh
September 2001
182. Genetics of Multiple Sclerosis MS Study Day, Neurology Department, The Royal Victoria
Infirmary, Newcastle upon Tyne
October 2001
183. New Treatment Strategies in MS [symposium]
Biogen, Vienna, Austria December 2001
184. Postgraduate Clinical Neurosciences Series
University of Cambridge Clinical School
March 2002
185. The Genetics of MS and Complex Traits
Royal London Hospital, London
March 2002
186. Canadian Collaborative Twin Study on Multiple Sclerosis: final report
Association of Physicians Cardiff April 2002
187. Natural History of Multiple Sclerosis, 1st Workshop
Bari, Italy May 2002
188. IFR Neurosciences Neurosciences Institute, Salpêtrière, Paris
June 2002
189. Genetics and Environmental Factors [in MS]
European Neurological Society, 12th Meeting, Berlin
June 2002
190. Insights into the Genetics of MS from the Canadian Collaborative Project
ACTRIMS/ECTRIMS 2002, Baltimore September 2002
191. Epidemiology and Genetics of MS: overview of immuno-therapy and role of interferon in MS
International Multiple Sclerosis, Jeddah
September 2002
192. Wellcome Trust Gene Centre: genetic studies in MS and in migraine
Neurosciences Meeting, Oxford September 2002
193. Repair of the Central Nervous System
National Multiple Sclerosis Society Workshop, Nice
October 2002
194. What We Think We Know
Roundtable on Primary Progressive Disease in MS, Houston

November 2002

195. Multiple Sclerosis Advanced Medical Conference, Royal College of Physicians,
London February 2003
196. Genetics of MS Neurosciences Seminar, University of Tübingen
February 2003
197. Truth, Knowledge and Power lecture series
St Hugh's College, University of Oxford
February 2003
198. Genetic Epidemiology of MS Erasmus MS Centre, Rotterdam April 2003
199. Natural History of MS Sylvia Lowry Centre, München April 2003
200. The Natural History of Untreated MS
2nd Dubrovnik International Conference on MS
May 2003
201. The Natural History of Chronic Variable Disease
MS Forum, 1st Annual Convention, Istanbul
June 2003
202. The Natural History of MS and Relevance of Genes to Outcome
ECTRIMS, Milan September 2003
203. MS Gene Discovery Efforts: The Canadian population
NINDS/NMSS Workshop, Washington DC
September 2003
204. MS: Disease Course and Natural History; Genetics of MS
1st MS Forum Regional Meeting, Bangkok
October 2003
205. Natural History of MS (2 papers)
Neurological Seminar, Heinrich Heine University,
Düsseldorf, Germany November 2003
206. The Genetics of MS MRC Immunology Seminar, Imperial College, London
November 2003
207. MS Genetics and the Genetics of Epidemiology
MSc in Human Molecular Genetics Seminar Series,
Imperial College, London November 2003
208. Natural History of MS and the Genetics of MS
2nd International Workshop on Longitudinal Data Collection
MS Australia, Hobart, Tasmania March 2004
209. Historical Evolution of MS Consortium of MS Centres
Toronto, Canada June 2004
210. The Vitamin D Story Canadian Congress of Neurological Sciences
Calgary, Canada June 2004
211. Natural History and the Relevance of Genes to Outcome

- 7th International Congress of Immunology
Venice, Italy September 2004
212. Poster presentation Genomic Imprinting Conference
Montpellier, France September 2004
213. MS: it is not what it seems Hôpital Neurologique Pierre Wertheimer
Lyon, France October 2004
214. Current MS Research and its Potential Clinical Application in the Future
Neurology in the 21st Century
University of Arizona College of Medicine
October 2004
215. MS Genetics Minisymposium on molecular and therapeutic aspects of MS
King's College, London, Guy's Hospital
December 2004
216. Pathogenesis of MS Wellcome Trust Centre for Human Genetics seminar
Oxford University April 2005
217. A Critique of Clinical Trials in MS
University of Padua, Italy May 2005
218. The Genetic Basis of MS International Symposium on new approaches to understanding
the basis of MS
Valencia, Spain June 2005
219. Genetic Epidemiology of MS Baltic Summer School
Copenhagen August 2005
220. The clinical course of MS: what it tells us about pathogenesis
EFNS Athens September 2005
221. MS: Evidence that Insufficient Sunlight is a Cause
Meeting on Vitamin D and sunlight
Dept of Health, Portucullis House November 2005
222. Determining Prognosis in MS/ Environmental Epidemiology of MS/HLA Genes in MS
World Congress in Neurology
Sydney, Australia November 2005
223. Canadian data MSRA Symposium on Genetics of MS
Sydney, Australia November 2005
224. The Eye, the Cord and the Waterhole
Medical Grand Round
John Radcliffe Hospital, Oxford January 2006
225. Multiple Sclerosis: Major Paradigm Shift – the Final Turn?
Internal seminar
Wellcome Trust Centre for Human Genetics,
Oxford January 2006
226. Episodic Ataxia International Episodic Ataxia Conference
Santa Monica, USA February 2006

227. The Environmental Epidemiology of MS
Update in Neurology Symposium
Cerrahpasa Medical School, University of Istanbul
March 2006
228. Prevention Possibilities and Challenges in MS
MS Australia Meeting
Sydney, Australia
March 2006
229. Analysis of bias in natural history studies
ECTRIMS Madrid
September 2006
230. The Eye, the Cord and the Waterhole
Medical Grand Round
John Radcliffe Hospital, Oxford
January 2006
231. Multiple Sclerosis: Major Paradigm Shift – the Final Turn?
Internal seminar
Wellcome Trust Centre for Human Genetics,
Oxford
January 2006
232. Episodic Ataxia
International Episodic Ataxia Conference
Santa Monica, USA
February 2006
233. The Environmental Epidemiology of MS
Update in Neurology Symposium
Cerrahpasa Medical School, University of Istanbul
March 2006
234. Prevention Possibilities and Challenges in MS
MS Australia Meeting
Sydney, Australia
March 2006
235. Analysis of bias in natural history studies
ECTRIMS Madrid
September 2006
236. Genetic Epidemiology of MS.
3RD International Course of Neuroepidemiology, Erice,
Sicily
November 2006
237. Are we closer to unlocking the mysteries of MS?
40th Anniversary meeting of MS Ireland
March 2007
238. Genetic Epidemiology of MS
Postgraduate Medical Centre, Gloucester Royal Hospital
March 2007
239. Multiple sclerosis: evolution and genetics
Henry Kunkel Society, New York
April 2007
240. Challenges in conducting a primary prevention trial: Vitamin D and MS

Harvard School of Public Health April 2007

241. MS: pathogenesis and therapeutic interventions.
Canadian Laboratory Medicine Congress
Toronto June 2007
242. MS: the inheritance of susceptibility.
MS Frontiers London
June 2007
243. Epidemiology of MS: results from the London Ontario database.
EFNS, Brussels August 2007
244. Gene-environment in Multiple Sclerosis
Istituto Besta. Milan October 2007
245. MS Genetics
ECTRIMS, Prague October 2007
246. Genetics in MS: the inheritance of MS susceptibility.
MS Life Manchester
March 2008
247. Susceptibility to multiple sclerosis: genes and environment. Seminar in Clinical Research.
Rockefeller University. April 2008
248. MS and Genetics. Royal London Hospital Rounds March 2008
249. The inheritance of multiple sclerosis susceptibility.
Henry Kunkel Society Annual meeting Genoa
May 2008
250. The Genetics of Outcome
Institut für Neuroimmunologie und Klinische Multiple
Sklerose Forschung (inims) May 2008
251. Genes and outcomes in MS: predicting disease severity
WCTRIMS Montreal September 2008
252. Debate: Interferons have been shown to prevent long term disability
Yes: G Comi. It remains uncertain: G.C. Ebers
CONy October 2008
253. National MS Register Audit.
MS Space Information Event Perth Scotland
November 2008
254. What does MS Epidemiology in Westerners Take/Teach?
PACTRIMS Kuala Lumpur
November 2008

255. Natural History of MS and Genetics of MS.
International Update in Clinical Neurosciences
Kolkata December 2008
256. Life style changes and demographic patterns of Multiple Sclerosis.
ECF Symposium Catania November 2008
257. Time of exposure of environmental factors in Multiple Sclerosis
ECF Symposium Catania November 2008
258. The role and mechanisms of HLA in the genetic susceptibility to MS.
CHU Hôpital Purpan Toulouse France.
April 2009
259. MS research and data. Conference for the Cornell
and Memorial Sloan Kettering faculty
Cornell University April 2009
260. Vitamin D and MS. Nutritionists in Industry London May 2009
261. The Use of Genetic Approaches in the Study of MS.
5th Aegean meeting on Neurologic Therapeutics Heraklion
May 2009
262. Vitamin D and genetics in MS
MS Life Gateshead June 2009
263. Environment versus or together with genetics".
ECTRIMS Dusseldorf September 2009
264. London MS Nature and Nurture.
Fison Lecture Kings College October 2009
265. Genetic Epidemiology of MS and Vitamin D.
Research Advisory Meeting MS Centre of Excellence Baltimore
October 2009
266. The research process illustrated by a "trivial" observation in MS.
A-Z of MS London October 2009
267. The relationship of clinically isolated syndromes and multiple sclerosis.
268. Family studies in multiple sclerosis: genes and environments
269. Neurogenetics in the new millennium. : Demyelinating diseases.
World Congress of Neurology Bangkok
October 2009
270. Genetics of MS XIX AINI Congress, Italy October 2009
271. The Natural History of multiple sclerosis.

- Sixth Aegean Meeting on Neurologic Therapeutics. Heraklion
May 2010
272. Pharmacoterrorism. Subtitle (Adult entertainment)
Brasenose Medical Society Oxford May 2010
273. Relapses and Long Term Outcome. MS Debating Society Burnham UK May 2010
274. Debate: Are placebo-controlled clinical trials still ethical/necessary in RRMS?
Yes: G. Ebers, UK
No: L. Kappos, Switzerland
CONy Barcelona October 2010
275. Epidemiology supporting the role of environmental factors in MS.
ECTRIMS Gothenburg October 2010
276. It's never been genes or environment. endMS Whistler December 2010
277. Interactions of environment and genes in MS. ECF Symposium Fiuggi December 2010
278. Genetic epidemiology of ms and vitamin d.
Scottish summit on vitamin D and MS. September 2010
279. Vitamin D and multiple sclerosis .
Vitamin D: mechanisms in health and disease. QMUL
March 2010
280. 3 Healthcare Systems. SENA Southampton October 2010
281. The feasibility of this study for demonstrating a significant reduction of the risk of MS in MS family members : where are the concerns ? Epidemiological, ethical, practical, financial.
ARSEP Paris May 2011
282. MS – a gene environment interaction. Belfast October 2011
283. The Cause of MS. Bergen September 2011
284. Vitamin D deficiency
Scientific symposium to celebrate the 50th anniversary of Multiple
Sclerosis Ireland. September 2011
285. Effects and complications of long-term treatment in MS you are scheduled to talk for 30-35 minutes
on Long-term follow-up studies in MS: what can we expect?
ENS Lisbon May 2011
286. Month of birth. Cheltenham Science Festival June 2011
287. Genetics and environment. The natural course of Multiple Sclerosis and the personal history of the
disease. Data from epidemiology.
ECF symposium December 2011
288. Vitamin D and MS. MS Frontiers. London June 2011

289. Environmental factors – targets for preventative strategies in MS.
ESNI Glasgow July 2011
290. Healthcare systems I have known. Hurstwood Park, The Princess Royal Hospital. September 2011
291. Clinician scientists – the case for.
Oxford Integrated Neurology Course. June 2011
292. Natural History of MS and what it means
SINS Santiago Chile July 2011
293. The role of vitamin D in MS. Modern Thinking and MS Management. Birmingham
February 2012.
294. The case for a prophylactic approach to Public Health and the hidden costs. Chatham House Debate
Glasgow March 2012
295. Osler was right about the environment – implications for MS prevention. Osler Club of London
May 2012
296. Sex ratio in MS – a surrogate for incidence – possible mechanisms. Sex, Gender, and Autoimmunity
Through the Lifespan. Chicago May 2012
297. What was learned by listening : MS so far. Oriol Medical Society April 2012
298. Life expectancy in MS. 44th Danube Symposium Szeged Hungary June 2012
299. Epidemiology & Genetics: what have we missed? Kyoto Japan Nov 2013
300. Twenty-five years in the history book of MS: short and long term efficacy and safety with IFNB-1b,
Society of the Hungarian Neuroimmunologists Esztergom, Hungary Nov 2013
301. Debate: Early treatment in MS: Does it make a difference?
Liverpool, UK March 2014